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ABSTRACT 
 
 
Intrinsically disordered proteins (IDPs) do not form stable tertiary structures like 
their ordered partners. They exist as heterogeneous ensembles that fluctuate over a 
time scale. Intrinsically disordered regions and proteins are found across different 
phyla and exert crucial biological functions. They exhibit transient secondary 
structures in their free state and become folded upon binding to their protein partners 
via a mechanism called coupled folding and binding. Some IDPs form alpha helices 
when bound to their protein partners. We observed a set of cancer associated IDPs 
where the helical binding segments of IDPs are flanked by prolines on both the sides. 
Helix-breaking prolines are frequently found in IDPs flanking the binding segment and 
are evolutionarily conserved across phyla. Two studies have shown that helix flanking 
prolines modulate the function of IDPs by regulating the levels of disorder in their free 
state and in turn regulating the binding affinities to their partners. We aimed to study if 
this is a common phenomenon in IDPs that exhibit similar pattern in the conservation 
of helix flanking prolines. We chose to test the hypothesis in c-Myb-KIX, IDP-target 
system, in which the disordered protein exhibits high residual helicity levels in its free 
state. 
c-Myb is a hematopoietic regulator that plays a crucial role in cancer by binding 
to the KIX domain of CBP. Studying the functional regulation of c-Myb by modulating 
the disorder levels in c-Myb and in IDPs in general provides a better understanding of 
the way IDPs function and can be used in therapeutic strategies as IDPs are known 
viii 
to be involved in regulating various cellular processes and diseases. To study the 
effect of conserved helix flanking prolines on the residual helicity levels of c-Myb and 
its binding affinity to the KIX domain of CBP, we mutated the prolines to alanines. 
Mutating prolines to alanines increased the helicity levels of c-Myb in its free state. 
This small increase in the helicity levels of a highly helical c-Myb showed almost no 
effect on the binding affinity between cMyb and KIX. We hypothesized that there is a 
helical threshold for coupled folding and binding beyond which helicity levels of the 
free state IDP have no effect on its binding to their ordered protein partner. To test 
this hypothesis, we mutated solvent exposed amino acid residues in c-Myb that reduce 
its overall helicity and studied its effect on the binding affinity between c-Myb and KIX. 
Over a broad range of reduction in helicity levels of the free state did not show an 
effect on the binding affinity but beyond a certain level, decrease in helicity levels 
showed pronounced effects on the binding affinity between c-Myb and KIX. 
1  
 
 
 
 
 
 
CHAPTER 1 
INTRODUCTION 
 
 
1.1 Intrinsically Disordered Proteins 
 
Most proteins adopt compact folded structures to exert cellular functions. They 
fold into stable tertiary and quaternary structures [1, 2] positioning the group of amino 
acid residues that are involved in the catalysis of various chemical reactions on the 
solvent-exposed side. In the past two decades, a set of proteins that do not fall into 
this category has been receiving recognition. These proteins, called the intrinsically 
disordered proteins (IDPs), are highly dynamic and do not form stable tertiary 
structures [3-5], but nevertheless are important for the functioning of the cell [3, 6-20]. 
They form specific heterogeneous conformational ensembles that fluctuate over time 
[21, 22]. 
IDPs are highly prevalent in nature and found across kingdoms especially with 
eukaryotes exhibiting a higher percentage of IDPs than algae and archaea [6, 23-25]. 
More than one-third of the eukaryotic proteins contain regions with disorder of over 30 
residues or higher in length [6, 7, 11, 26]. Eukaryotic transcription factors [27] and 
disease-associated proteins are rich in intrinsic disordered regions (IDRs) [9, 28-30]. 
IDPs regulate several biological processes like transcription, translation, cell 
signalling, cell proliferation, etc. All these processes are regulated through post 
translational modifications [31, 32], alternative splicing [33, 34], insertions and 
deletions [35], and alternative open reading frames [36]. Post translational 
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modifications [31] and either small molecule ligand [31, 37] or macromolecular protein 
binding induces IDRs or IDPs to become structured, or structured domains to become 
unstructured [38]. Disorder to order transition is known to be involved in the regulation 
of many cellular processes [39]. 
 
 
1.1.1 Structure and Composition of IDPs – Ordered v/s Disordered 
Proteins 
Composition of amino acid residues varies greatly between disordered and 
ordered proteins [4, 6, 40-43]. IDPs exhibit a low sequence complexity with a low 
fraction of hydrophobic residues and a high fraction of polar-charged residues [5, 44- 
47]. Ordered proteins are rich in non-polar and hydrophobic residues that collapse into 
a compact hydrophobic core thus stabilising their structure. The depletion of 
hydrophobic residues in IDRs prevents the formation of a hydrophobic core, catering 
to its flexibility. The presence of a high fraction of charged residues in IDPs allows 
repulsion of the neighbouring amino acid residues, further preventing and destabilizing 
the formation of a compact structure thus facilitating in the maintenance of their 
flexibility. Acidic and basic amino acids and structure-breaking amino acid residues 
like prolines and glycines are abundantly found in IDRs [5, 48]. These structure- 
preventing amino acids further extend the IDRs allowing multiple points of attachment 
when encountering their binding partners. Disordered regions are also depleted of 
aromatic amino acids. They exhibit high sequence variability including multiple 
insertions and deletions [35, 49]. Long insertions and deletions usually are associated 
with disordered regions [35, 50]. The flexibility of disordered regions allows binding to 
multiple protein partners [13, 41, 51, 52], which is a common feature of IDPs. 
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IDPs, with constant fluctuations in their conformational ensembles and high 
repulsions between neighbouring residues, do not maintain an equilibrium state for the 
positions of their atoms and bond angles thus rendering flexible backbone dihedral 
angles, phi and psi [7, 53]. All proteins maintain some level of flexibility in aqueous 
solutions. Despite this fact, ordered proteins, including non-folded structures like 
loops, are comprised of ensembles with all its members having nearly identical 
Ramachandran angles. Contrary to that, disordered proteins are comprised of 
ensembles with individual members possessing unique Ramachandran angles [45]. 
Disordered regions exist in a broad range of the structural spectrum from completely 
unfolded to partially folded to structures with near natively folded conformations, i.e., 
collapsed, extended or intermediates between collapsed and extended forms [11, 45, 
54, 55]. As previously described, IDPs are comprised of a high fraction of charged 
residues. Disordered proteins with a significant net charge exist as extended forms; 
the higher the fraction of like charges, the higher the extension in the disordered region 
[3, 56, 57]. IDPs that possess a net neutral charge along with a few hydrophilic amino 
acid residues exist in collapsed forms, forming random structures but not defined 
secondary structures. Such proteins fall under the pre-molten globule class of IDPs [3, 
22]. Disordered proteins with a significant fraction of hydrophobic residues i.e., IDRs 
that possess structure-promoting sequence patterns, but insufficient folding energy 
exist as collapsed forms with stable secondary structures but unstable or no tertiary 
interactions. This class of IDPs is termed molten globules [3, 58]. 
While ordered proteins are classified into different groups based on their 
secondary structures [1, 2], the broad range of structural differences in disordered 
regions concomitant with their failure to fold into complex structural levels, makes it 
difficult to classify IDPs into distinct groups [45]. Despite the difficulty, attempts have 
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been made to classify disordered proteins into various classes based on their 
structure, sequence, biophysical and functional features [59]. They are further grouped 
into different classes based on their evolution and interactions with other proteins [59]. 
IDPs can be recognized and studied by various techniques such as to Circular 
Dichroism (CD), Nuclear Magnetic Resonance (NMR) Spectroscopy, Optical Rotatory 
Dispersion (ORD), X-ray Crystallography [6, 11, 60]. Among all the available 
techniques, NMR is well suited for studying IDPs [61]. Disordered regions can be 
distinguished from ordered regions by a far U.V spectrum from CD analysis, and low 
chemical shift dispersions and negative nuclear overhauser effects (NOEs) from NMR 
analysis. 
 
 
1.1.2 Functions of Intrinsic Disordered Proteins and Intrinsic Disordered 
Regions 
Disordered proteins and regions are functional in all their structural forms i.e., 
pre-molten and molten globules, and extended forms. IDPs are vital in regulating 
numerous biological processes by binding to other proteins [15, 16, 62], nucleic acids 
[34, 63-66] and are also involved in ribosomal assembly [39, 67, 68], allosteric 
regulation [69-73] and chaperone activity [8, 38, 74, 75]. Post-translational 
modifications like methylation, acetylation, phosphorylation and ubiquitination are 
known to be linked to disordered proteins and regions [15]. Apart from participating in 
molecular recognition and assembly, as in the case of ribosomal assembly, disordered 
regions play a pivotal role in complex protein-protein interaction networks acting as 
network hubs [13, 76-78]. In the current section some of the functional roles of IDPs 
are described in detail. 
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1.1.2.1 Solubility enhancement. Protein solubility is dependent upon the 
interactions of amino acid residues with water. Ordered proteins are collapsed into a 
compact hydrophobic core exposing the polar, charged residues to the solvent- 
exposed side. Charged residues interact with water leading to the solubility of protein 
in aqueous solutions [59]. There are some hydrophobic residues on the solvent- 
exposed side that interact with other proteins. These residues combined with the 
denaturation of folded regions lead to the exposure of a significant fraction of 
hydrophobic residues that are not in favour of interacting with water, sometimes 
leading to aggregation and precipitation. Disordered proteins are not folded into 
compact structures and are rich in polar, charged residues. Charged residues 
favourably interact with water, aiding in the solubility of IDRs. Compact globular 
structures are susceptible to denaturation by heat; disordered regions failing to fold 
into stable tertiary structures are resistant to heat denaturation. One such example is 
the cyclin dependent kinase inhibitor protein, p21, that plays a key role in apoptosis. It 
was found to be stable and soluble for a wide range of temperatures ranging from 5- 
90 ⁰C [52]. In fact, early analysis and purification of disordered proteins was done by 
denaturation of proteins by heat [79]. Therefore, disordered proteins pose an 
advantage in laboratory protein expression and purification, over ordered proteins [80]. 
Studies have been performed where addition of disordered proteins as tags to 
naturally poorly-soluble proteins was shown to enhance the solubility of the protein 
[81, 82]. 
1.1.2.2 Chaperones. Chaperones are proteins that assist in folding of other 
proteins and RNA [83-87]. Intrinsic disordered regions are abundantly found in 
chaperones; half of the RNA chaperone sequences and one-third of protein chaperone 
sequences are disordered [87, 88]. Disordered regions are well adapted to be 
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chaperones. Their lack of definite structure allows them to bind to multiple binding 
partners and, therefore, are suitable for binding to a wide range of protein and RNA 
molecules. Interactions involving disordered regions are faster when compared to 
those involving only ordered regions. This is because the unfolded structure of IDRs 
allows easy access to multiple amino acid residues, making recognition by their 
binding partners easier. IDPs constantly fluctuate between different conformational 
ensembles, which allows numerous non-specific interactions between IDPs and their 
binding partners, ultimately increasing the life-time of the bound complex [89, 90]. This 
quick interaction and prolonged association time with disordered chaperones gives 
sufficient time for the misfolded protein to unfold and refold correctly. Fast interaction 
between disordered chaperones and misfolded proteins also helps in preventing the 
formation of aggregates and consequent precipitation, by enhancing the solubility of 
the misfolded protein [59]. 
1.1.2.3 Post-translational modifications. IDPs are associated with an 
enormous number of post-translational modifications, as many as a million [8, 16, 24, 
91]. This enormity emphasizes the importance of intrinsically disordered proteins in 
cellular signalling and regulation. The flexibility of disordered regions facilitates easy 
access to modifying enzymes such as kinases and acetylases for recognition and 
binding. Flexibility of disordered regions also enables transient interactions between 
IDRs and modifying enzymes [92, 93]. Upon binding of the modifying enzyme, 
disordered proteins lose their conformational entropy, in turn leading to a reduction in 
the overall free energy of binding, which results in a weak interaction. Processes 
involving post-translational modifications require binding of the protein to more than 
one macromolecule i.e., the modifying enzyme and the receptor molecule. Disordered 
proteins are well suited for this because unstructured regions can fold into different 
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conformations required for different targets [8]. Disordered regions are known to be 
highly enriched in phosphorylation sites [93, 94]. 
 
 
1.1.3 Coupled Folding and Binding 
 
Coupled folding and binding involves the binding and folding of an 
intrinsically disordered protein to their protein partner to exert important cellular 
functions. IDPs exhibit transient secondary structures in free state but fold upon 
binding to their protein partners the process of which is termed as coupled folding and 
binding. Two mechanisms namely conformational selection and induced fit are 
believed to be linked to coupled folding and binding. The mechanism by which IDPs 
bind to their targets has been debated for decades but evidences have shown that 
IDPs bind to their partners by either of the extreme mechanisms or both together. 
 
 
 
 
Figure 1: Coupled folding and binding. Mechanism of coupled folding and binding 
showing induced fit and conformational selection mechanisms. IF denotes induced fit 
and CS denotes conformational selection. 
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In the conformational selection mechanism, disordered protein which fluctuates 
between different conformations adopts a conformation that is close to the IDP in its 
bound form which is then followed by binding to its protein partner (Figure 2) i.e., a 
conformation is selected for binding and hence the name, conformational selection. In 
the induced fit mechanism, disordered protein makes a couple of weak interactions 
with its ordered protein which is followed by its folding and subsequent tight interaction 
with its protein partner. 
 
 
1.1.4 Evolution of IDPs 
 
IDRs show higher mutation rates than ordered proteins [49] which is expected 
since these proteins unlike ordered proteins don’t possess a compact hydrophobic 
core that needs to be preserved. Despite high mutation rates, certain amino acid 
residues like tyrosine, tryptophan, leucine, phenylalanine and proline are highly 
conserved in IDRs [6, 42, 44]. 
 
 
1.2 Myeloblastosis Protein, c-Myb 
 
c-Myb (Myeloblastosis protein) is a hematopoietic transcription factor that plays 
a crucial role in regulating cellular differentiation and cell proliferation [95-99]. It 
decides the fate of the cell i.e., decides whether the cell proceeds with continuous 
proliferation or cell cycle arrest is induced and the cell starts differentiating. c-Myb is 
highly conserved and is found not only in insects and vertebrates but also in some 
plants and invertebrates [99-101]. Reduction or loss of c-Myb function is linked to 
embryonic lethality and most human leukemias, colorectal, breast and some epithelial 
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cancers [96, 99, 102-108]. c-Myb is abundantly expressed in hematopoietic cells but 
is also seen in other types of cells [109-112]. 
 
 
1.2.1 History of c-Myb 
 
c-Myb belongs to the myb family of transcription factors, which, like c-Myb, are 
highly conserved and act as transcriptional coactivators. The other members of the 
family include A-Myb and B-Myb which are structurally similar to c-Myb with minute 
differences which are discussed in the next section [113]. Myb gene, termed v-Myb, 
was originally discovered as an oncogene in chicken leukemia viruses, Avian 
Myeloblastosis Virus and E26 virus [114]. It was later revealed that v-Myb is a 
truncated version of c-Myb that was transduced by the viruses from chicken cells [114, 
115]. c-Myb is the normal cellular counterpart of v-Myb and hence the name c-Myb 
which means cellular Myb. 
 
 
1.2.2 Structure of c-Myb 
 
The proto-oncogene c-Myb is translated into two protein forms. The major 
translated form is a 75 kDa residue protein that acts a hematopoietic transcriptional 
activator. It consists of a conserved N-terminal DNA binding domain, an acidic 
transcriptional activation domain and a C-terminal specificity and negative regulatory 
domain (Figure 2). The C-terminal domain consists of various motifs with specific 
functions. It includes a “FAETL” domain that is responsible for its oncogenic activity 
[116], an “EVES” domain that is responsible for intramolecular and intermolecular 
interactions during negative regulation of the protein [117]. It also consists of a 
“TPTPF” domain whose function is unknown. Poly-proline regions are also seen in the 
C-terminal domain and are speculated to be involved in conformational changes [95]. 
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Figure 2. Schematic diagram of members of the Myb protein family. It shows the 
DNA binding domain (DBD), transactivation domain (TAD) and negative regulatory 
domain that has various amino acid residue motifs. Blocks with PP represent the poly- 
proline rich regions. Box with 9A in c-Myb 89 kDa schematic diagram represents the 
protein encoded from alternative splicing. 
 
 
The minor translated form of c-Myb arises from alternative splicing of the proto- 
oncogene which is seen in hematopoietic cells of birds, mice and humans [118-120]. 
It is an 89 kDa protein which comes from an alternative splice form that results in the 
addition of a 363-bps fragment between exons 9 and 10. This region was given the 
name exon 9A. A-Myb and B-Myb are structurally similar to c-Myb though they have 
specific functions (Figure 2). DNA binding domain and the “TPTPF” domains are seen 
in A-Myb and B-Myb, too. v-Myb also shows structural similarities with c-Myb. 
Although, DNA binding domain and the transactivation domain from c-Myb are 
conserved in v-Myb, several truncations are seen in the N- and C-terminal regions. v- 
Myb from AMV virus also has eleven point-mutations throughout the length of the 
protein that are shown to contribute to its oncogenic activity [121-123]. v-Myb from 
E26 virus is a complex form of v-Myb where an oncogenic peptide is added to the C- 
terminus region. Both v-Myb proteins show truncations in the C-terminus region and 
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are responsible for oncogenicity thus implying that the C-terminus region of c-Myb has 
tumour suppressing activity [124, 125]. c-Myb exhibits disorder levels throughout its 
structure as shown in figure 3. 
 
 
 
 
Figure 3: Disorder plot of full length c-Myb. Figure shows the disorder tendency 
plot of full length c-Myb obtained from the IUPRED predictor aligned with the 
schematic diagram of c-Myb. Values above 0.5 suggest disorder level tendencies. 
 
 
1.2.3 Functions of c-Myb 
 
As mentioned previously, c-Myb is a DNA binding protein that acts as a 
transcriptional activator and plays a key role in cell proliferation and differentiation. 
Functions of each domain in the protein are described below. The N-terminal DNA 
binding domain (DBD) binds specifically to the consensus sequence PyAACT/GG that 
is known as the MYB binding site (MBS) [126]. It consists of three tandem sequence 
repeats R1, R2 and R3 of approximately 50 amino acid residues long, which are highly 
conserved [99, 127, 128]. All these three repeats consist of tryptophans separated by 
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18-19 amino acid residues and are highly conserved among all Myb proteins and 
across species [99, 113, 128]. R2 and R3 repeats contain two helix-turn-helix motifs 
and are required for the binding of c-Myb to DNA, and R1 is responsible for the 
stabilization of DNA-R2R3 complex. The hydrophobicity of conserved aromatic 
tryptophan residues in the tandem repeats is essential for maintaining the stability of 
helix-turn-helix motifs [129]. Transactivation domain of c-Myb binds to several proteins 
and transactivates the expression of multiple genes thus regulating several cellular 
processes including but not limited to cell cycle regulation and cell signalling. This 
study is focussed on its binding to the CREB-Binding Protein (CBP), a histone acetyl 
transferase. The mechanism of this interaction is described in detail in the later section 
of this chapter. The C-terminal domain is responsible for negative regulation of the 
protein. Studies involving deletion of C-terminal sequences in c-Myb and v-Myb, which 
lacks the C-terminal region, show an increase in the transcriptional activity of c-Myb 
[124, 130]. 
1.2.3.1 Role in hematopoiesis and adult brain neurogenesis. c-Myb 
regulates cell proliferation and differentiation in hematopoietic progenitor cells and 
neural progenitor cells [131]. Early studies have linked c-Myb’s role to hematopoiesis 
[132-135]. c-Myb knockout mice die of anoxia during embryogenesis at day 15. A loss 
in almost all blood cell lineages and a reduced growth of fetal liver is seen in these 
mice which implies that c-Myb is essential in the early stages of development [136]. 
Expression of c-Myb is generally restricted to progenitor cells and is downregulated as 
cells begin differentiating [135, 137]. Overexpression of c-Myb prevents differentiation 
of myeloid and erythroid lineages [138, 139]. An exception to this is seen in B and T 
cell lymphocyte differentiation, which require the presence of c-Myb at almost all 
stages although its expression is downregulated as cells differentiate. T cell 
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differentiation pathway requires expression of c-Myb at all stages except for the early 
stages i.e., differentiation of DN1 (double negative 1) and DN2 cells [140]. 
Differentiation of DN3, DN4 and DP (double positive) cells require c-Myb. Likewise, B- 
cell differentiation pathway requires the expression of c-Myb to differentiate from pro- 
B cells to pre-B cells to B cells [141]. 
In adult vertebrates, new neural cells are continuously produced and 
differentiated throughout the lifetime of an individual. Conditional knock out of c-Myb 
in mice brain, caused defects in adult brain neurogenesis and was linked to decreased 
expression of crucial neurogenesis genes Pax6 and sox2. Knockout mice show 
defects in neural progenitor cells leading to reduced or no production of new neural 
cells, enlarged ventricle spaces and defects in the circulation of cerebrospinal fluid 
[131]. 
1.2.3.2 Cell cycle regulation. Activity of c-Myb is highest during late G1 phase 
and S phase. Destruction of c-Myb RNA arrests cell cycle at G1 phase which implies 
that c-Myb is essential for cell cycle progression. c-Myb is known to regulate a number 
of genes that are linked to cell growth, like stem cell growth factor c-kit [142], fibroblast 
growth factor FGF2 [143] and DNA topoisomerase IIα [144]. c-Myb also regulates the 
expression of bcl-2 which is responsible for apoptosis [145]. 
 
 
1.2.4 Role in Cancer 
 
c-Myb is linked to leukemia, breast, and colon cancers but is also known to be 
related to other cancers like melanoma, oesophageal and pancreatic cancer [131]. c- 
Myb is required for the proliferation and survival of chronic myeloid leukemia (CML) 
and acute myeloid leukemia (AML) cells, and its over-expression is observed in both 
cancers [146, 147]. Duplication and translocation of c-myb gene is observed in T cell 
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acute lymphoblastic leukemia [148, 149]. Over expression of c-Myb is also seen in 
more than 80% of the cases in colorectal cancers [150-152]. Mutations in the first 
intron of c-myb, which is linked to its regulation by transcriptional elongation (see 
‘regulation of c-myb’ section), are found in primary colorectal cancers [105]. In other 
studies, performed using primary colorectal cancer genomic DNA, hypermutations in 
the poly T tract and the stem loop were also observed [106]. 
 
 
1.2.5 Regulation of c-Myb 
 
c-Myb has a half-life of approximately thirty minutes [131]. Activity of c-Myb is 
regulated by altering its protein levels through various post translational modifications 
including phosphorylation, acetylation, sumoylation and ubiquitylation. Mature c-Myb 
RNA is restricted to hematopoietic cells and intestinal epithelial tissues although 
differentiation in hematopoietic cells results in the reduction of c-Myb levels. 
 
 
 
 
Figure 4. Model representing c-Myb regulation through elongation control. 
Figure shows the poly T tract present in c-Myb gene. It also shows the RNA stem loop 
that binds to elongation control proteins abrogating their access to DNA binding. ERα 
binds upstream of the poly T tract and induces transcription. 
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Expression of c-Myb is tightly regulated by blocking transcriptional elongation 
in the first intron [105-107, 153-156]. Region in the human c-myb gene that is 
responsible for the attenuation of its expression consists of a poly T tract of 19-23 
thymidine residues that binds to an RNA stem loop eventually blocking its transcription 
(Figure 4). Poly T tract is preceded by a region which encodes an RNA stem loop that 
interacts with elongation control proteins like positive elongation transcription factor B 
(PTEB) [105, 106]. In colon cancers, a reduction in the size of poly T tract and/or 
mutation in the region encoding the RNA stem loop can occur, leading to an increased 
expression of c-Myb and cellular proliferation. In breast cancers, oestrogen receptor- 
α interacts with the gene when bound to oestradiol which relieves elongation block. 
 
 
1.2.6 c-Myb Target Genes and Binding Partners 
 
c-Myb target genes include genes that are responsible for proliferation such as 
CCNA1, CCNB1, CCNE1, MYC, KIT, BCL2. Target genes linked to differentiation 
include MIM1, CD4, PTCRA, ELA2 among others. c-Myb also targets a few 
housekeeping genes like GSTM1 and MAT2A. 
The most important protein-protein interaction for c-Myb is binding to the CREB 
binding protein (CBP a.k.a. p300) through its transactivation (TAD) domain. c-Myb 
binds to the KIX domain of CBP/p300 via coupled folding and binding [157, 158]. 
Interaction between CBP and c-Myb is described in detail in the later sections of the 
chapter. c-Myb also binds to another co-activator, p100, through its DNA binding 
domain. Binding of c-Myb DNA binding domain to p100 is believed to abrogate the 
intramolecular interaction between DNA binding domain and the EVES motif in C- 
terminal regulatory domain by competing with it. Phosphorylation of S528 from the 
EVES motif reduces c-Myb activity [117]. It is speculated that phosphorylation of S528 
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induces intramolecular binding and thereby c-Myb transactivation is inhibited. p100 
disrupts this binding and relieves the inhibition. The C-terminal regulatory domain of 
c-Myb binds to a variety of protein partners. The FAETL motif, which lies in the leucine 
zipper, is responsible for transactivation and transforming ability. Mutation of FAETL 
motif and leucine zipper results in increased transcriptional activity revealing that it is 
involved in negative regulatory interactions [116, 159, 160]. 
 
 
1.2.7 CREB Binding Protein (CBP), c-Myb’S Binding Partner 
 
CREB (cAMP response element binding protein) binding protein (CBP) is a 
transcriptional co-activator that binds to several proteins including general 
transcription factors and DNA in a sequence specific manner [161, 162]. CBP binds to 
a broad range of proteins that are involved in crucial cellular processes like cell growth, 
differentiation, DNA repair and apoptosis [163, 164]. CBP exhibits an inherent acetyl 
transferase activity with which it acetylates not only the histone tails of chromosomes 
but also some proteins and transcription factors like c-Myb [165]. 
A schematic diagram of CBP, with all its functional domains is shown below 
(Figure 5). CBP is a 2441 amino acid residue protein that includes the following 
domains: 1) A nuclear receptor interaction domain which binds to the DNA and 
promotes transcription of adjacent genes. 2) A cysteine- and histidine-rich domain 
called the TAZ1 domain that binds to proteins such as p53, MDM2 and E1A. 3) KIX 
domain that binds to CREB, p53, c-Myb, STAT1 and BRCA1. 4) A bromo-domain. 5) 
A second cysteine-histidine (CH2) rich domain. 6) A histone acetyl transferase activity 
(HAT) domain. 7) A zinc finger. 8) TAZ2 domain that binds to proteins such as p53, 
TFIIB, E2F, E1A and GATA1. 9) A Nuclear Co-Activator Binding Domain [164, 166, 
167]. 
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Figure 5: Schematic diagram of mammalian CBP. Above picture represents all the 
functional domains of CBP. Domains with known structures are shown in color. 
Abbreviations are given to each domain, which are explained in the text. 
 
 
1.2.8 Interaction Between c-Myb TAD and the KIX Domain of CBP 
 
The transactivation domain of c-Myb binds to the KIX domain of CBP via 
coupled folding and binding. This interaction results in the activation and transcription 
of many genes that are linked to biological functions. c-Myb transactivation domain 
exhibits disorder levels in its free state. An IUPRED plot of c-Myb TAD disorder is 
shown in Figure 6. 
 
 
 
 
 
Figure 6: Disorder tendency of c-Myb TAD as predicted using IUPRED. Disorder 
tendency plot of c-Myb TAD obtained from the IUPRED predictor. Values above 0.5 
suggest disorder levels. Schematic diagram of full length c-Myb is placed on top of the 
plot. 
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Figure 7: Figure showing mechanism of c-Myb activation by CBP. KIX domain of 
CBP binds to the transactivation domain of c-Myb while CH2 domain of CBP binds to 
the negative regulatory domain (NRD). Upon binding of CH2 domain to the NRD of c- 
Myb, the acetyl transferase activity domain in CBP acetylates lysine residues at 
positions 436 and 441. Acetylated c-Myb binds to the enhancers of DNA and promotes 
transcription of downstream genes. 
 
 
CBP binds to the transactivation and regulatory domains of c-Myb through its 
KIX and CH2 domains respectively (Figure 7). When the CH2 domain of CBP binds 
to the regulatory domain of c-Myb, the histone acetyltransferase activity region in CBP 
acetylates lysine 437 and lysine 448 residues of c-Myb that are present in the region 
containing TPTPF motif. Acetylated c-Myb is translocated in-to the nucleus and 
activates transcription. 
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1.3 Specific Aims 
 
Intrinsically disordered proteins do not form tertiary structures but exhibit 
transient secondary structures in aqueous solutions. They are involved in various 
protein-protein interactions and become folded upon binding to their ordered proteins 
via a process called coupled folding and binding. Many IDPs, like the transactivation 
domain of c-Myb exhibit transient helical structures in free state that resemble their 
bound structures. Conserved prolines are found flanking the helical binding segments 
of some cancer associated IDPs. We hypothesized that the levels of transient helicity 
in the free state disordered proteins regulate the binding affinity of IDPs to their protein 
partners. Previous studies have shown that increasing the transient helicity levels of 
p53, a tumour suppressor protein, and MLL, mixed lineage leukaemia protein, in their 
free state affects their binding affinities to MDM2 and KIX respectively. It was observed 
that conserved helix flanking prolines regulate transient helicity levels in both these 
systems. Do conserved helix flanking prolines regulate transient helicity levels of 
disordered proteins and in turn the binding affinities to their protein partners in all 
IDPs? We aimed to study the effect of changing transient helicity in c-Myb TAD, which 
exhibits high levels of transient helicity in its free state, on its binding affinity to the KIX 
domain of CBP. To test our hypothesis, we designed the following aims. 
 
 
Aim 1 (Chapter Two) - Study the effect of conserved helix flanking prolines on the 
transient helicity levels of c-Myb TAD and its binding affinity to the KIX domain of CBP. 
 
 
Aim 2 (Chapter Three) – Study the effect of changing transient helicity levels of c-Myb 
TAD on its binding affinity to the KIX domain of CBP by mutating solvent exposed sites 
in c-Myb TAD. 
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CHAPTER 2 
 
EFFECT OF CONSERVED HELIX FLANKING PROLINES ON THE STUCTURE 
AND BINDING AFFINITY OF IDPs TO THEIR TARGETS 
 
 
Note to the readers: This chapter contains published data from Biochemistry, 2017, 
15: 2379-2384, and has been reproduced with permission. 
 
 
2.1 Rationale: Conservation of Prolines in c-Myb TAD and Other IDPs 
 
As discussed previously, a common phenomenon observed in IDPs is that they 
fold upon binding to their protein partners via coupled folding and binding [168]. Some 
of these proteins exhibit transient helical structure in aqueous solution and form 
amphipathic alpha helices upon binding to their ordered protein partners. Proline 
residues are frequently found flanking the helical binding regions in these IDPs (Figure 
8) [5, 169]. If prolines, known helix breakers, are commonly seen flanking the helical 
binding segments in disordered proteins, and are conserved across species, it was 
speculated that they play a crucial role in biological function and that they might be 
doing so by regulating the levels of disorder in IDPs. In this study, the effect of 
conserved helix flanking prolines on the structure and function of IDPs is tested in the 
transactivation domains of three IDPs. Figure 8 shows the alignments of 
transactivation domains of three IDPs, namely p53, c-Myb and MLL, that form alpha 
helices when bound to their respective protein partners. The rest of the chapter is 
focussed on studies conducted using the human sequences of transactivation 
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domains all the IDPs shown in the figure 8. The influence of conserved helix flanking 
prolines in these IDPs and their effects on the transient helicity levels and the binding 
affinities to their ordered protein partners is described in this chapter. 
 
 
 
 
 
 
Figure 8: Alignment of IDPs showing conserved helix flanking prolines. Above 
picture shows conserved helix flanking prolines in three IDPs in various species 
(human, mouse, chicken, frog and zebrafish) adapted from previously published 
material [170]. These IDPs form alpha helices when bound to their protein partners. 
Bound complexes taken from PDB are shown to the right: IDPs in grey and ordered 
partners in red. Starting from the top, p53:MDM2 (PDB ID 1YCR), MLL:CBP KIX (PDB 
ID 2LXS) and c-Myb:CBP KIX (PDB ID 1SB0). Cyan spheres represent helix flanking 
prolines. Prolines that are not present in the PDB structures are represented as cyan 
spheres. N represents the N-terminal end of IDPs. Alignments shown in the middle 
panel were obtained using Clustal Omega. Helix flanking prolines are highlighted in 
blue in a black shaded area and regions that form alpha helices upon binding are 
shown in red. Grey shaded area represents the region used in the structure. Asterisks 
denote regions that are fully conserved. Colons indicate regions that are conserved 
with strong similar amino acid properties and period denotes sequences conserved 
with weak similar amino acid properties. This figure is taken from “Conserved Helix 
Flanking Prolines Modulate Intrinsically Disordered Protein:Target Affinity by Altering 
the Lifetime of the Bound Complex,” by Crabtree MD et.al., 2017, Biochemistry, 56, p. 
2379. CC-BY. 
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2.2 Evidence of Conserved Helix Flanking Prolines Regulating the Binding 
Affinity Between IDP and Target 
Previously published work shows the effect of conserved helix flanking prolines 
in p53 and MLL on their binding affinity to their respective protein interaction partners 
[170]. Structural and functional roles of conserved helix flanking prolines in these IDPs 
is studied by mutating the N- and C-terminal prolines to alanines. Structural effects 
were analysed by nuclear magnetic resonance spectroscopy, an excellent tool to study 
IDPs. The immediate effect of removal of prolines on the function of IDPs, the binding 
affinity to their protein partners, is studied using isothermal titration calorimetry and 
binding kinetics were measured using stopped-flow fluorescence techniques. 
 
 
2.2.1 Effect of Conserved Helix Flanking Prolines on the Residual 
Structure of IDPs 
NMR experiments were performed on uniformly 15N and 13C labelled MLL and 
p53. Proteins were purified as described in [170] and dialysed in NMR buffer. HSQC 
and three dimensional HNCACB and HNCO experiments were performed at 25 ⁰C and 
assignments were made as described in chapter 5. When the C-terminal proline was 
mutated in p53, the peak residual helicity of the resultant mutant in free state was 
increased approximately by 40% (Table 1). N-terminal proline mutations did not show 
a significant change in the residual helicity of p53. In MLL, the C-terminal proline 
mutation had no effect on the residual helicity in the free state while the N-terminal 
proline showed an increase in the helicity of the binding region by approximately 1.4- 
fold (Figure 9). The increase in the helicity for MLL was uniform across the length of 
the helix but the ppm change observed was within the digital resolution of the NMR 
experiments. 
  
 
Peptide Helicity (NMR) 
Helicity 
(CD) 
Kd    
Equilibrium 
(nM) 
Kd Kinetics 
(nM) 
kon 
(x106 M-1 s-1) 
 
koff (s-1) 
p53 WT 3 n.d 240 ± 60 176 ± 8 25 ± 1 4.40 ± 0.03 
 
p53 P27A 
 
6 
 
n.d 
 
25 ± 3 
 
n.d 
 
30.7 ± 0.7 
fast, 0.37 ± 0.01 
slow, 0.072 ± 
0.005 
p53 P12/13A 3 n.d 220 ± 30 n.d 22 ± 2 n.d 
p53 
P12/13/27A 6 n.d 17 ± 6 n.d 32.4 ± 0.9 n.d 
MLL WT 2 13 600 ± 60 530 ± 30 24 ± 1 12.4 ± 0.3 
MLL P21A n.d 14 700 ± 120 560 ± 15 22.0 ± 0.6 12.22 ± 0.08 
MLL P9/21A 3 16 17000 ± 2000 
9000 ± 
6000 20 ± 14 200 ± 16 
MLL L8A n.d 12 35000 ± 4000 n.d n.d 170 ± 14 
 
 
 
Table 1: Helicity and binding data of WT and mutant p53 and MLL. Table shows the average helicity of the peptides derived from 
CD and NMR analyses. It also shows the dissociation rate constants, kon and koff rates of WT and mutant peptides obtained from the 
interaction. Binding affinities of complexes obtained from kinetic and equilibrium studies are listed in the table. This table is adapted 
from “Conserved Helix Flanking Prolines Modulate Intrinsically Disordered Protein:Target Affinity by Altering the Lifetime of the Bound 
Complex,” by Crabtree MD et.al., 2017, Biochemistry, 56, p. 2379. CC-BY. 
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2.2.2 Influence of Helix Flanking Prolines on the Binding Affinity of 
IDP:Target 
Binding affinities between IDPs and their partners were measured using 
equilibrium binding experiments and stopped flow kinetics. The proline to alanine 
mutants of p53 and MLL showing a change in residual helicity have a change in the 
binding affinity to their ordered partners but the sign of the changes is different. 
 
 
 
 
 
 
Figure 9: Fractional helicity plots of MLL and p53 showing the differences in 
residual helicity between WT and mutants. Figure in the top panel shows the 
change in residual helicity between p53 P27A and p53 WT while the bottom panel 
shows the change in residual helicity between MLL P9/21A and MLL WT. In the top 
figure, only the segment of the peptide showing a change in the residual helicity is 
shown. This figure is taken from “Conserved Helix Flanking Prolines Modulate 
Intrinsically Disordered Protein:Target Affinity by Altering the Lifetime of the Bound 
Complex,” by Crabtree MD et.al., 2017, Biochemistry, 56, p. 2379. CC-BY. Reprinted 
with permission. 
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In p53 P27A, an increase in the residual helicity resulted in an increase in the 
binding affinity by 10-fold (Figure 10, Table 1). Conversely, in MLL, an increase in the 
residual helicity of P9/P21A showed a 25-fold reduction in the binding affinity between 
MLL and KIX. Data obtained from these experiments suggests that prolines alter the 
binding affinity of IDPs to their targets by regulating the residual helicity levels of IDPs 
in their free state, but it also implies that an increase in the residual helicity of IDPs 
doesn’t always enhance their binding affinities. 
 
 
 
 
 
 
Figure 10: Fold change in the binding affinities, and association and 
dissociation rate constants of IDPs to their targets. Error bars for association and 
dissociation rate constants represent the error in the fit except for MLL double mutant 
where error bars denote the standard deviation of the mean (n=7). Error bars for Kd 
represent the standard deviation of the mean where n=3. This figure is taken from 
“Conserved Helix Flanking Prolines Modulate Intrinsically Disordered Protein:Target 
Affinity by Altering the Lifetime of the Bound Complex,” by  Crabtree  MD  et.al., 
2017, Biochemistry, 56, p. 2379. CC-BY. Reprinted with permission. 
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A 1.4-fold increase in helicity levels in MLL led to 25-fold reduction in binding 
affinity. Is this change in binding affinity coming entirely from the change in the amount 
of helical content in free state MLL or by disrupting the binding interface between MLL 
and KIX? To answer this question, we aimed to mutate the leucine residue, which is 
immediately N-terminal to the proline at position 9, that sits in the hydrophobic pocket 
of KIX. This mutation (L8A) showed a 53-fold reduction in the binding affinity of MLL 
and KIX (Figure 10). 
Prolines altering binding affinities in a different manner in each IDP emphasizes 
the need to study the mechanism behind regulation of binding affinities by levels of 
transient residual helicity. Stopped-flow fluorescence experiments were performed to 
analyse the kinetics of IDP:target binding. 
 
 
2.2.3 Mechanism of Regulation 
 
Binding kinetics experiments revealed a change in the dissociation rate 
constant in both the IDP-target systems. In p53 P27A mutant, association rate 
constant showed less than 1.2-fold reduction when compared to WT. Two dissociation 
rate constants were seen with P27A and the fastest of the two rates showed a 12-fold 
reduction when compared to wild type (Figure 11). In MLL P9/21A too, the association 
rate constant was unaffected while there was a 15.8-fold increase in the dissociation 
rate constant. The change in affinity in MLL L8A and KIX interaction corresponds to a 
13.9-fold increase in the dissociation rate constant with no apparent changes in the 
association rate constant (Figure 11, Table 1). These studies suggest that the 
conserved helix flanking prolines regulate the binding affinities between IDPs and their 
targets, not by enhancing the rate of complex formation, but by altering the stability of 
the complex through dissociation rates. 
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Figure 11: Binding kinetics studies of p53:MDM2 and MLL:KIX. A and C show 
observed association rate constants observed under pseudo-first order conditions of 
p53 and MDM2 respectively with an excess of MDM2 and KIX respectively. 
Association rate constant, kon is obtained from a gradient of the straight-line fit. B and 
D show observed dissociation rate constants of p53 and MLL obtained from 
competition studies. This figure is taken from “Conserved Helix Flanking Prolines 
Modulate Intrinsically Disordered Protein:Target Affinity by Altering the Lifetime of the 
Bound Complex,” by Crabtree MD et.al., 2017, Biochemistry, 56, p. 2379. CC-BY. 
Reprinted with permission. 
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2.3 Influence of helix flanking prolines on the binding of c-Myb to KIX 
 
N- and C-terminal prolines in the transactivation domain of c-Myb at positions 
289 and 316 were mutated to alanines, as described in section 5.6, resulting in two 
mutants, c-Myb P289A and c-Myb P289A P316A. Detailed description of the 
expression and purification of proteins is outlined in sections 5.1 and 5.2. 
Concentration of proteins was calculated using their extinction coefficients and the 
absorbance of U.V light at 280 nm. Protein samples were dialysed into suitable buffers 
before analysis according to the protocols described in chapter 5. Circular dichroism 
and nuclear magnetic resonance spectroscopy were used to determine the 
percentage of alpha helical content in mutant and WT c-Myb TAD peptides. 
 
 
2.3.1 Prolines influence the transient helicity of c-Myb 
 
Circular dichroism (CD) is a rapid technique that can be used to study the 
secondary structures of peptides and proteins. Secondary structures can be 
distinguished from each other by their unique shapes in a far U.V spectrum. Alpha 
helices show characteristic dips in molar ellipticity of circularly polarized light at 222 
nm and 208 nm and peak at 196 nm. The magnitude of the dip at 222 nm is 
proportional to mean helicity of the peptide. Detailed description of the procedure for 
collecting and analysing CD spectra is outlined in section 5.3. 
CD experiments were performed in a far U.V. range (190-260 nm) using Jasco 
J-815 spectropolarimeter at 25 ⁰C in a 0.1 mm path length cell. Proteins were dialysed 
by a million-fold in three steps and the experiments were conducted at a concentration 
of 1mg/ml. Mutation of prolines to alanines showed an increase in helicity in both the 
mutants. (Figure 12). Close observation of the curves reveals a greater dip in the 
mutants when compared to wild type indicating higher helicity levels. Molar residual 
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ellipticity and average helicity of the peptides were calculated as described in [171, 
172] (Table 2). Mutating the N-terminal proline at position 289 to alanine increased 
the mean helicity by 1.28-fold. Mutating both the N- and C-terminal prolines increased 
the mean helicity by 1.35-fold when compared to WT. 
 
 
 
 
 
 
Figure 12: CD plot of WT and proline mutants of c-Myb. Molar residual ellipticities 
of all the peptides were plotted against wavelength. Black curve represents the molar 
ellipticities of WT c-Myb while red and blue represent the same for P289A and P289A 
P316A respectively. Molar ellipticities were obtained from the mean of the two CD 
accumulations collected using the same sample. 
 
 
Although, CD is advantageous over other techniques in obtaining a quick 
measurement, it gives only a global measurement of the helicity levels of peptide. 
Residue specific information such as the residues involved in helix and the region of 
the peptide where the mutations caused changes cannot be determined from CD 
analysis. This emphasizes the need to perform NMR analysis, a technique which gives 
residue specific information of secondary structures. 
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2.3.2 Residue specific analysis of the transient helicity levels of c-Myb 
and the proline mutants 
NMR experiments were performed for c-Myb WT, P289A and P289A P316A to 
obtain information on helicity at the residual level. NMR analysis gives information on 
the residues specifically affected by the mutation and the mechanism of increased 
helicity i.e., whether the increased helicity resulted from an increase in the amount of 
helix per residue or an elongation in the length of the helix. HSQC and 3D HNCACB 
and HNCO experiments were conducted on all three peptides at 25 ⁰C as described 
in section 5.4. 
 
 
Peptide % Helicity (CD) 
WT 20.81 
P289A 26.75 
P289A P316A 28.22 
 
 
 
Table 2: Percentage helicity of c-Myb WT and proline mutants. Above table shows 
the percentage helicity of c-Myb WT and mutants calculated from molar residual 
ellipticity values at 222 nm. % Helicity was calculated using molar ellipticities obtained 
from two CD accumulations collected using the same sample. 
 
 
As seen in CD analysis, both the N-terminal and C-terminal proline mutants 
show an increase in the helicity level. Some residues could not be assigned which are 
indicated in the chemical shift tables in Appendix B. Figure 13 shows alpha carbon 
secondary chemical shifts of WT and mutant c-Myb along with the δ2D curves. 
Secondary chemical shifts are an accurate measure to determine the secondary 
structures of peptides and proteins. Information from alpha carbon chemical shifts can 
be used to measure the helicity of peptides. Secondary chemical shifts were calculated 
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by subtracting the chemical shifts of random coils from the chemical shift data obtained 
from assignments. Secondary chemical shifts are used to calculate residual helicity 
percentages using δ2D analysis developed by Vendruscolo [173]. Mean helicity of 
each peptide was obtained from the sum of helicities of all the residues in the peptide. 
NMR analysis showed a 1.23-fold increase in the mean helicity when the N-terminal 
proline is mutated to alanine. When both the prolines were mutated to alanines, there 
was a 1.28-fold increase in the mean helicity (Table 3). Mean helicity values obtained 
from CD and NMR analysis complement each other (Table 3). 
 
 
Peptide % Helicity (CD) 
% Helicity 
(NMR) 
WT 20.81 21.8 
P289A 26.75 26.9 
P289A P316A 28.22 28 
 
 
 
Table 3: Average helicity of c-Myb WT and proline mutants obtained from CD 
and NMR analysis. Helicity values obtained from CD are an average of two 
accumulations collected using the same sample. 
 
 
Changes in helicity were observed at and around the sites of mutation in both 
the mutants. The helix is extended on the N- and C-terminal regions when respective 
prolines were mutated to alanines. NMR analysis also reveals that the region in WT c- 
Myb TAD that forms an alpha helix is highly helical in its free state i.e., most of the 
residues involved in the helix have a helical propensity greater than 75% (Figure 13). 
It must be noted that, though we see an increase in the mean helical content of the 
peptide, the amount of increased helical content at the residue level is less than two- 
fold. 
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Figure 13: Alpha carbon secondary chemical shifts and δ2d analysis of c-Myb 
WT and proline mutants. Figure shows the α carbon secondary chemical shift 
deviations (ΔδCα, black bars) and the residual helical percentages (red smoothed 
lines) for WT and mutants of c-Myb TAD. X-axis shows the sequence used in all our 
studies. Prolines used in mutations are shown in red. Grey shaded region represents 
the region that binds to the KIX domain of CBP. Some assignments couldn’t be made 
which is mentioned in Appendix B. Missing data points in residual helicity percentages 
are joined as a smooth curve. 
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2.3.3 Characterisation of Binding Affinity Between c-Myb and the KIX Domain of 
CBP 
Isothermal titration calorimetry (ITC) was used to study the effect of 
increased helicity in c-Myb mutants. Data was collected with an excess of c-Myb at 25 
⁰C on a set of three samples prepared from the same culture preparation and average 
of the three runs is calculated (Table 4). WT and mutant c-Myb peptides were used at 
a concentration of 0.15 mM and KIX was used at a concentration of 15 μM. ITC is an 
accurate way of measuring binding affinity as it is extremely sensitive to a very small 
change in heat. It measures the heat utilized or released during a chemical reaction 
from which the enthalpy and association constants of the reaction can be deduced. 
Twenty-nine small injections of concentrated c-Myb were titrated into KIX in our 
experiments. Heat traces of all the injections were then integrated and a curve was 
plotted using a single-site binding model. Titration curves from one of the three runs 
of each peptide are shown in Figure 15. 
The change in residual helicity in both the proline mutants showed almost no 
effect on their binding affinities to the KIX domain of CBP. Mutating N-terminal proline 
to alanine showed a 1.24-fold increase in the dissociation constant implying that the 
increase in helicity resulted in a reduction in the binding affinity between c-Myb TAD 
and the KIX domain of CBP (Figure 15). Mutating both the N- and C-terminal prolines 
to alanines resulted in a 1.06-fold increase in the dissociation constant which also 
implies that the increased helicity led to a reduction in binding affinity. But, these small 
changes in binding affinity (Table 4) fall under the error level of the instrument. 
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Figure 15: ITC curves of c-Myb WT and proline mutants. Y-axis denotes the heat 
of injection in Kcal/mol. Each solid circle on the plot represents each injection. X-axis 
represents the ratio of protein to ligand at the time each injection. Curves from one of 
the three runs with each peptide is shown. 
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Peptide % Helicity (CD) 
% Helicity 
(NMR) Kd (μM) 
WT 20.81 21.8 0.5 ± 0.03 
P289A 26.75 26.9 0.62 ± 0.02 
P289A 
P316A 28.22 28 0.53 ± 0.02 
 
 
 
Table 4: Average helicity and binding affinity of c-Myb WT and proline mutants. 
Combined table showing mean helicity of peptides obtained from CD and NMR 
experiments. Kd is calculated from the association constant obtained from ITC. Error 
represents the standard deviation of mean from three ITC runs. 
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CHAPTER 3 
 
CHARACTERISING THE RELATIONSHIP BETWEEN DISORDER LEVELS AND 
BINDING AFFINITY IN c-Myb TAD 
 
 
3.1 Rationale 
 
Mutations of conserved helix flanking prolines did not show any effect on the 
binding affinity of c-Myb to KIX but showed an effect in the binding affinities of p53 and 
MLL to their respective protein partners. Do levels of disorder in the free state of IDP 
regulate binding in all IDPs? Does c-Myb TAD fall under such a category? Is there a 
helical threshold for energetic penalty in coupled folding and binding? To answer these 
questions, we developed a model of c-Myb TAD – KIX where we designed mutations 
in c-Myb TAD with levels of transient helicity that are less than WT with the goal of 
reducing the transient helicity to a point where we observe a reduction in binding 
affinity. Since these mutations were made in the region of c-Myb helix that binds to 
KIX, care was taken to ensure we did not mutate any residues that directly contact 
KIX. Binding experiments were performed on the mutants to study the relationship 
between disorder levels of c-Myb TAD and its binding affinity to the KIX domain of 
CBP. 
 
 
3.2 Examining the Binding Interface Between c-Myb and KIX 
 
To accurately measure the effect of disorder levels on the binding affinity, it is 
important to ensure that the mutants created are not largely different in their structures 
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from WT. Mutations must be created in such a way that the overall charge and 
structure of the peptide is preserved. To account for the change in binding affinity 
entirely to the change in disorder levels in free state, it is also crucial to ensure that 
the binding interface is not altered. To satisfy all the above-mentioned conditions, the 
structure of the complex between c-Myb TAD and the KIX domain of CBP was 
examined and sites that are not involved in the binding were chosen for mutagenesis 
(Figure 16). Solution structure of the KIX domain of CBP bound to mouse c-Myb TAD 
that is deposited in Protein Data Bank is taken as a reference for analysis [174]. Eight 
residues that don’t interact with KIX residues in the binding were found in the helical 
region of the transactivation domain of c-Myb. From the eight available sites, four sites 
were selected based on the reductions in helicities predicted by the Agadir software 
which is described in detail in the next section. Among these four residues, two of them 
are on the N-terminal side of the helix (E292, K293), one residue is closer to the N- 
terminal region (K296) and one residue is right in the middle of the helix (L300) and is 
adjacent to the leucine that sits in the hydrophobic pocket of KIX. 
 
 
3.3 Designing Mutations in Solvent Exposed Sites 
 
Residues at positions 292 (E), 293 (K), 296 (K) and 300 (L) were selected for 
mutations. Change in helicity was predicted with several conservative amino acid 
substitutions in the four locations using Agadir software. Agadir is an algorithm used 
to predict alpha helical content in peptides. pH and temperature were set to our 
experimental conditions and Agadir was run with several amino acid substitutions. 
From the Agadir data obtained, mutations with significant change in helicity were 
picked and mutants were made using site directed mutagenesis as described in 
section 5.6. 
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Figure 16: Amino acid interactions between c-Myb TAD and the KIX domain of 
CBP. Residues in the left, highlighted in blue represent amino acid residues of c-Myb 
TAD that form an alpha helix when bound to KIX. Residues to the right, highlighted in 
green are KIX residues that are involved in binding. Arrows indicate the residues 
interacting with each other. Type of interaction is not shown in the picture. Residues 
highlighted in red are the residues in the helical region that do not participate in 
binding. 
 
 
As the residual helical content of c-Myb TAD in the helical region is already high 
in its free state, only mutations with significant predicted reduction in helicity were 
chosen  for  experimental  studies.  Mutating  the  residues  with  a  goal  of  helicity 
enhancement is not advantageous since these mutations might not enhance the 
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helicity of already highly helical c-Myb TAD to a significant extent that can show an 
impact on the binding affinity between c-Myb TAD and KIX. Despite this fact, one 
mutation that is predicted to enhances the helicity of free state c-Myb TAD was used 
for analysis which is described below. Mutations, E292D, K293H, K296H and L300V, 
were chosen for our studies based on the predicted helical propensities by Agadir 
software (Table 5). Leucine at position 300 was also mutated with proline and glycine, 
known helix breakers, to obtain a mutant with promising reduction in helicity. Leucine 
at position 300, being in the middle of the helix should show a greater impact on 
modulating the residual helicity of free state IDP. Apart from all these mutations, the 
G311A mutant was also made. This glycine to alanine mutation, as predicted, should 
enhance the helicity of c-Myb TAD in its free state. Glycine at position 311, being closer 
to the binding segment when compared to the proline to alanine mutation at position 
316, is a good candidate to study the effect of enhanced helicity on binding affinity. 
 
 
Peptide % Helicity (Agadir) 
G311A 19.29 
WT 19.23 
E292D 13.45 
K293H 11.01 
K296H 7.94 
L300V 15.48 
L300G 8.12 
L300P 4.74 
 
 
 
Table 5: Percentage helical prediction of single amino acid substitutions in c- 
Myb TAD using Agadir. Agadir calculates the mean percentage helicity from the 
residual helical propensities that it predicts. Amino acids substitutions were also picked 
based on the amount of reduction/change in helicity observed in the helical region of 
predictions. Percentage helicity of WT as predicted by Agadir is also shown. 
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3.4 Modulating Levels of Transient Helicity in c-Myb TAD 
 
 
3.4.1 Analysis of Alpha Helical Content by Circular Dichroism 
 
Circular dichroism was first used to study and analyse the structures of mutants 
as it is economical, and results can be obtained in a short period of time. NMR 
spectroscopy was then performed on the mutants that showed a high change in 
helicity levels to investigate the residual helicity changes in each one of them. Circular 
dichroism was performed in the same way as proline mutants. Detailed outline of the 
procedure is described in section 5.3. Mutants were expressed and purified in the 
same way as WT c-Myb although the induction times for each of the mutants varied 
which is outlined in section 5.2. From circular dichroism analysis, it was observed that 
mutants show changes in helicity levels as predicted by Agadir, but in the changes in 
mean helicity of mutants are not as pronounced as Agadir predicted (Table 6). 
 
 
Peptide % Helicity (Agadir) % Helicity (CD) 
G311A 19.29 24.31 
WT 19.23 20.81 
E292D 13.45 20.53 
K293H 11.01 16.28 
K296H 7.94 19.38 
L300V 15.48 17.39 
L300G 8.12 14.21 
L300P 4.74 7.77 
 
 
 
Table 6: Differences in helicity percentage levels as predicted by Agadir and as 
experimentally observed by CD. Percentage helicity of observed and predicted WT 
and mutant c-Myb TADs are shown in the table. Although, Agadir over-estimated the 
reduction in helicity, it follows the general trend as experimental values, as shown in 
the table. 
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Change in helicity level of E292D mutant was almost none while L300P and 
L300G showed substantial reductions in the levels of transient helicity (Figure 17 and 
Figure 18). L300V also revealed a strong reduction in helicity levels, although it is not 
as pronounced as the other leucine mutants. Reduction of helicity in K293H and 
K296H is not in compliance with the rest of mutants and we think this could be due to 
the isomerization of histidine residues at the pH used. Further analysis should be done 
on these mutants at varying pH levels to study the pH dependence. 
 
 
 
 
Figure 17: CD plot of c-Myb mutants and WT. Curve in black denotes the molar 
ellipticity of WT c-Myb while red, green and blue represent molar residue ellipticity of 
mutants in the decreasing order of helicity levels i.e., G311A, E292D and L300V 
respectively. Data for K293H and K296H are not shown in the plot. 
42  
Based on the NMR and CD data obtained for proline mutants described in 
chapter 2, information obtained from CD can be relied upon. Plots are separated in 
two graphs to better notice the changes in curves that are close (Figure 17 and Figure 
18). Figure 17 shows a dip in the G311A curve at 222 nm when compared to WT 
indicating that the helicity level is increased. Calculating the mean helicities from molar 
residual ellipticities revealed a 1.19-fold increase in the helicity level for G311A. E292D 
and L300V shows reductions in the dip at 222 nm indicating a reduction in the helicity 
levels. Mena helicity calculations revealed a 1.19-fold reduction in the helicity in 
L300Vmutant while there is almost no change in the helicity level in E292D. K293H 
and K296H showed 1.26- and 1.07-fold reductions in the helicity levels respectively 
when compared to WT(Table 6). Curves in figure 17 and values from table 6 suggest 
that these conservative mutations have affected the residual helicity levels but not at 
a level where we can see an impact on their binding affinities to the KIX domain of 
CBP. 
L300P and L300G curves from figure 18 show a reduction in the dip at 222 nm 
when compared to WT thus implying that the levels of transient helicity were reduced. 
In the case of L300P, the curve is almost flat at 222 nm. Careful observation of the 
curves reveals a shift in the dips of L300P and L300G from 208 nm to the left, shifting 
towards the characteristic curve of a random coil. This suggests that the transient 
helicity levels in these mutants were disrupted on a greater level. From the mean 
helicity level calculations, we noticed a 1.46-fold and 2.67-fold reductions in the helicity 
levels of L300G and L300P respectively. NMR analysis was performed on the mutants 
that showed outstanding reduction in helicity levels i.e., L300P and L300G to 
characterize the changes in helicity at residual level. 
43  
 
 
 
 
Figure 18: CD plot of WT c-Myb and leucine mutants. Red curve indicates L300P 
while blue curve represents L300G and black curve represents WT molar residual 
ellipticity data. 
 
 
3.4.2 Characterizing the Alpha Helical Content at Residual Level 
 
NMR analysis showed similar reductions in the mean helicity levels as seen 
with CD (Figure 19). E292D shows a 1.18-fold reduction in the mean helicity while 
L300G and L300P showed 1.57- and 3.96-fold reductions in the mean helicity levels 
respectively. Table 7 shows a comparison of mean helicity data obtained from Agadir 
and experimental analysis. Examining the helicity curves from figure 19 reveals a 
reduction in helicity at and around the site of mutation, at least until three residues on 
both the sides of mutation. Leucine at position 300, being in the middle of the helix 
showed pronounced reductions in the levels of helicity at and around the site of 
mutations when mutated to proline and glycine. In L300G, the helix was disrupted until 
seven residues N-terminal to the site of mutation and a couple of residues on the C- 
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terminal side of the mutation. A 25% reduction in the peak helicity was observed. In 
L300P, helix was disrupted entirely around the site of the mutation, until three residues 
on both the sides of the mutation which includes the leucine residue that sits in the 
hydrophobic pocket of KIX. It also reduced the helicity levels until seven residues N- 
terminal to the site of mutation reducing the peak helicity by almost half. 
 
 
Peptide % Helicity (Agadir) 
% Helicity 
(CD) 
% Helicity 
(NMR) 
G311A 19.29 24.31 n.d 
WT 19.23 20.81 21.8 
E292D 13.45 20.53 19.2 
L300V 15.48 17.39 n.d 
L300G 8.12 14.21 13.8 
L300P 4.74 7.77 5.5 
 
 
 
Table 7: Comparison of mean percentage helicities of WT and mutant c-Myb 
obtained from Agadir, CD and NMR. Table shows the mean percentage helicity 
values of WT and mutant c-Myb peptides as predicted from Agadir and experimentally 
verified using CD and NMR analysis. n.d represents not determined. 
 
 
3.5 Characterization of binding affinity of mutant c-Myb to the KIX domain of 
CBP 
Binding affinities were measured on the mutants created except for the lysine 
to histidine mutants. Experimental conditions were kept the same as proline mutations. 
Since the leucine mutations showed a greater level of reduction in helicity, we 
expected a weak binding between c-Myb TAD and KIX with these mutants. Hence, the 
concentrations of proteins used for binding experiments was increased when 
compared to wild type to obtain a decent signal. 
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Figure 19: Alpha carbon secondary chemical shifts and δ2D plots of Leucine 
mutants and E29D. Figure shows the α carbon secondary chemical shift deviations 
(ΔδCα, black bars) and the residual helical percentages (red smoothed lines) for WT 
and mutants of c-Myb TAD. X-axis shows the sequence used in all our studies. Sites 
of mutations are shown in red. Grey shaded region represents the region that binds to 
the KIX domain of CBP. Some assignments couldn’t be made which is mentioned in 
Appendix B. Missing data points in residual helicity percentages are joined as a 
smooth curve. 
46  
L300G binding was measured at a five-fold increase in the concentrations of 
protein and ligand while L300P was measured at a ten-fold increase in the 
concentrations. There was a 1.26- and 1.64-fold increase in the dissociation constants 
when E292D and L300V were titrated into KIX respectively implying the binding affinity 
is reduced in both the cases (Figure 20 and Table 8). We noticed a 1.08-fold reduction 
in the dissociation constant when G311A was titrated into KIX which suggests that the 
increased helicity in G311A resulted in an increased binding affinity between c-Myb 
TAD and the KIX domain of CBP. Introducing glycine at position 300 further weakened 
the binding affinity which was explained by a 4.5-fold increase in the dissociation 
constant suggesting a weak binding between c-Myb TAD and KIX. Binding affinity 
between L300P and KIX was very small, marked by a 600-fold reduction in the binding 
affinity, implying that the binding between c-Myb TAD and KIX was almost entirely 
abolished when a proline was introduced in the middle of the helix (Figure 20). L300P 
binding was repeated a couple of times with a sample size of three and the results 
were consistent. 
 
 
Peptide % Helicity (CD) 
% Helicity 
(NMR) Kd (μM) 
G311A 24.31 n.d 0.46 ± 0.03 
WT 20.81 21.8 0.5 ± 0.03 
E292D 20.53 19.2 0.63 ± 0.02 
L300V 17.39 n.d 0.82 ± 0.05 
L300G 14.21 13.8 2.24 ± 0.02 
L300P 7.77 5.5 290 ± 101 
 
 
 
Table 8: Comparison of helicity and binding affinities of WT and mutant c-Mybs. 
Observed helicity percentages obtained from both techniques are shown in the table. 
n.d denotes not determined. 
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Figure 20: Binding curves of c-Myb conservative and leucine mutants. WT curve 
is shown for a comparison. All the curves were fit using a single site binding model. 
Curves represent data from a single run. Each sample was run with three runs. 
 
 
Mean association constants measured directly by the instrument were used to 
calculate dissociation constants shown in Table 8. Standard deviation was obtained 
from dissociation constant values from three sample runs. L300P shows a high error 
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in the binding affinity but catering to the low/no binding affinity as seen in the curve, 
and the error of the instrument, such high errors are expected. ∆G values were 
calculated from association constants obtained from the experiment using the formula: 
∆G = -RTlnKa 
 
where, R is the gas constant, T is the temperature, in degrees Kelvin, at which the 
experiment was performed, and Ka is the association constant. Table 9 shows the list 
of all c-Myb mutants and WT along with their helicities, binding affinities and ∆G 
values. 
 
 
 
Peptide 
% 
Helicity 
(CD) 
% Helicity 
(NMR) 
 
Kd (μM) ΔG Kcal/mol 
P289A 
P316A 28.22 28 0.53 ± 0.02 -8.56 
P289A 26.75 26.9 0.62 ± 0.02 -8.46 
G311A 24.31 n.d 0.46 ± 0.03 -8.64 
WT 20.81 21.8 0.5 ± 0.03 -8.6 
E292D 20.53 19.2 0.63 ± 0.02 -8.46 
L300V 17.39 n.d 0.82 ± 0.05 -8.3 
L300G 14.21 13.8 2.24 ± 0.02 -7.7 
L300P 7.77 5.5 290 ± 101 -5 
 
 
 
Table 9: Comparison of helicities and binding affinities of WT and all mutant c- 
Mybs. Observed helicity percentages obtained from both techniques are shown in the 
table. n.d denotes not determined. Dissociation constants were calculated as a mean 
from association constants obtained from three sample runs. Error represents the 
standard deviation of the mean. ∆G values were calculated from association 
constants. 
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CHAPTER 4 
DISCUSSION 
 
 
4.1 Effect of Prolines on Residual Helicity and Binding Affinity in p53:MDM2 and 
MLL:KIX systems 
The effect of prolines on the residual helicity of free state IDPs was studied 
using nuclear magnetic resonance spectroscopy. Mutating helix flanking prolines to 
alanines resulted in an increase in the residual helicity in both systems. We observed 
a 1.5-fold increase in the mean helicity in MLL while there was a two-fold increase in 
the mean helicity in p53, when the helix flanking prolines were mutated to alanines. 
The effect of increased helicity on the binding affinity to their ordered partners was 
studied using equilibrium binding experiments and stopped-flow kinetics. An increase 
in the helicity of free state IDP is expected to result in an increase in the binding affinity 
of the bound complex. As expected, we noticed a 10-fold increase in the binding affinity 
of p53 and MDM2 when the C-terminal proline is mutated. A one percent increase in 
the helicity of free state MLL, that resulted from mutating N-terminal proline to alanine, 
led to a 25-fold reduction in the binding affinity between MLL and KIX, opposite of what 
we expect. 
The mechanism behind changes in binding affinity in p53:MDM2 and KIX:MLL 
complexes was studied using stopped-flow kinetics. A ten-fold reduction in the 
dissociation rate constant was observed when the C-terminal proline was mutated to 
alanine in p53. We noticed a 15.8-fold increase in the dissociate rate constant when 
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N-terminal proline is mutated to alanine in MLL. Kinetic studies revealed that the 
changes in binding affinity are caused by changes in dissociation rate constants but 
not association rate constants implying that the influence of conserved helix flanking 
prolines is not on the rate of complex formation but on the stability of the bound 
complex which indicates that in both these cases, the mechanism of binding is 
induced-fit. 
A one-percent increase in helicity in MLL corresponding to a 25-fold reduction 
in the binding affinity between MLL and KIX did not seem real. This huge reduction in 
binding affinity might be explained by the loss of proline side chain interactions with 
KIX caused by the mutation. We questioned if the huge reduction in binding affinity is 
coming solely from the loss of proline side chain interaction or from the disruption of 
binding interface. Examining the bound structure of MLL and KIX revealed a leucine, 
immediately N-terminal to the proline, that packs into a hydrophobic pocket in KIX 
(Figure 8). Mutating this leucine to alanine (L8A) showed a 53-fold reduction in the 
binding affinity between MLL and KIX (Table 1). A 13.9-fold increase in the 
dissociation rate constant was observed in MLL L8A – KIX complex which we think is 
majorly contributing to the 15.8-fold reduction in the dissociation rate constant in 
P9/21A mutation. These results indicate that the 25-fold reduction in binding affinity 
seen in P9/21A mutation is predominantly coming from the disruption of the interaction 
between leucine and KIX. Prolines are known to influence the conformation of residues 
preceding them. This suggests that proline to alanine mutation in MLL disrupted its 
binding affinity to KIX not by altering the amount the helix but by changing the direction 
of the polypeptide. 
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4.2 Effect of Conserved Helix Flanking Prolines in the c-Myb Transactivation 
Domain on the Binding Affinity Between c-Myb and the KIX Domain of CBP 
Effect of conserved helix flanking prolines on the helicity of the free state c-Myb 
was studied using circular dichroism and nuclear magnetic resonance spectroscopy. 
Mutating N- and C-terminal prolines resulted in a 1.2- and 1.3-fold increase in the 
helicity levels as observed by circular dichroism. NMR spectroscopy revealed changes 
in helicity levels at and around the sites of mutations. Mean helicity levels from CD 
and NMR spectroscopy complement each other. NMR spectroscopy revealed that the 
free state of c-Myb is highly helical i.e., the residual helicities of most of the amino acid 
residues in the helical region range between 80 – 90%, the peak residual helicity being 
92.1%. Increase in helicity levels showed almost no effect on the binding affinity 
between c-Myb TAD and the KIX domain of CBP. An increase in the helicity levels not 
showing any effect on the binding affinity between an already highly helical c-Myb and 
its ordered protein KIX might indicate that there is a helical threshold level beyond 
which any changes in the helicity levels do not influence the binding affinity between 
IDP and its ordered protein partner. If such a threshold level exists, we think that WT 
c-Myb TAD is above this threshold level while WT p53 is below this apparent threshold 
level. 
 
 
4.3 Effect of solvent exposed amino acid substitutions in c-Myb TAD on its 
Binding Affinity to the KIX Domain of CBP 
Solvent exposed amino acid sites in c-Myb TAD were utilized for mutations to 
reduce its overall helicity. Conservatives mutations in the solvent exposed sites were 
made at positions 292, 293, 296 and 300 resulting in mutations E292D, K293H, K296H 
and L300V. All these conservative mutations showed slight reductions in the helicity 
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levels which in turn showed very small reductions in the binding affinity between cMyb 
TAD and KIX. CD analysis revealed almost no change in the helicity levels with E292D 
mutation while L300V mutation showed a 1.2-fold reduction in helicity levels. Although, 
lysine to histidine mutations at positions 293 and 296 showed reduction in the helicity 
levels when compared to WT, they do not follow the same trend with Agadir predictions 
as our other mutations. Preliminary studies indicated that this might be resulting from 
ionization of histidine at our experimental pH levels. Binding experiments were not 
performed on these mutants. E292D mutation showed a 1.26-fold reduction in the 
binding affinity while L300V mutation showed a 1.3-fold reduction. 
Conservative mutations showed a broad range in the reduction of helicity but 
did not show a significant reduction in the binding affinity between c-Myb TAD and 
KIX. We aimed to reduce the helical content further to go below the helical threshold 
we hypothesized by introducing helix-breaking amino acid residues in the middle of 
the helix. To achieve this, leucine at position 300 was mutated to either glycine or 
proline. A 1.5-fold reduction in the helicity level was observed from CD and NMR 
studies when leucine at position 300 was mutated to glycine. Mutating leucine at 
position 300 to proline resulted in a 2.6-fold and 3.96-fold reductions in the helicity 
levels obtained from CD and NMR studies, respectively. NMR studies revealed a 
reduction in the helicity levels at and around the site of mutation in L300G while in 
L300P mutation the helix is completely disrupted at the site of mutation along with 
reducing the helical content on the N-terminal side of the mutation. Isothermal titration 
calorimetry experiments showed a four-fold reduction in the binding affinity between 
c-Myb L300G and KIX when compared to WT-KIX complex binding affinity. A very 
weak binding, marked by a 600-fold reduction in binding affinity, was observed 
between L300P and KIX. Introduction of helix-breaking amino acid residues like 
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proline and glycine might also change the inherent structure of the peptide. Hence, it 
is important to make sure that the weak binding affinities in L300P and L300G 
mutations are not arising from a disrupted binding interface between c-Myb TAD and 
KIX but solely by changes in the residual helicity levels of free state c-Myb. Chemical 
shift mapping experiments must be performed with KIX bound to WT and mutant c- 
Myb to determine whether the binding interface between c-Myb TAD and KIX is 
disrupted by introducing proline/glycine. 
 
 
4.4 Conclusion 
 
We think that the helix flanking prolines regulate the binding affinity of IDPs to 
their ordered proteins by regulating the disorder levels of IDPs in their free state, but 
the mechanism of regulation might differ in each IDP. In the case of p53, conserved 
helix flanking prolines regulate the binding affinity between p53 and MDM2 by tuning 
the amount of helical content in the region that forms helix. This is explained by an 
increase in the amount of helix caused by proline to alanine mutations. In the case of 
MLL, conserved helix flanking prolines regulate the binding affinity between MLL and 
KIX by holding the direction of polypeptide such that the leucine preceding the N- 
terminal proline packs in the hydrophobic pocket of KIX. Conserved helix-flanking 
prolines in an already highly helical cMyb TAD do not have any effect on its binding 
affinity to the KIX domain of CBP. Reducing the helicity of cMyb TAD over a broad 
range did not show a high reduction in the binding affinity but introducing either a 
proline or glycine showed pronounced effects on the binding affinity between c-Myb 
TAD and KIX (Figure 22). Our results indicate that there might be a helical threshold 
level for energetic penalty in coupled and binding and we think introducing 
proline/glycine in c-Myb TAD reduced its helicity levels to below this apparent helical 
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threshold level. Helix-coil-transition theory further explains our results. Formation of 
the first H-bond in an alpha helix requires the immobilisation of four amino acid 
residues but the formation of subsequent H-bond interactions require the 
immobilisation of only one amino acid residue per each H-bond interaction. We think 
introducing proline/glycine in the middle of the helix in c-Myb TAD disrupted the 
formation of the first H-bond destabilizing the helix and thus resulting in a weak binding 
affinity. 
 
 
 
 
 
Figure 21: Correlation plot of % Helicity and binding affinity of WT and mutant 
c-Myb peptides. % Helicity values obtained from CD and binding affinities from ITC 
are drawn as a plot to show the relation between levels of disorder and binding affinity 
between c-Myb and KIX. 
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CHAPTER 5 
MATERIALS AND METHODS 
 
 
5.1 KIX Sample Preparation and Purification Scheme 
 
 
5.1.1 Synthesis and Sub-Cloning 
 
The human KIX gene (residues 586-672), synthesized from Eurofins, was 
cloned into pET-28a vector. The vector is selected for kanamycin resistance and 
consists of T7 promoter which is followed by a six-histidine tag and a thrombin 
cleavage site (Figure 1). KIX plasmid was inserted downstream of T7 promoter in the 
multiple cloning site between BamHI and XhoI restriction sites. 
 
 
5.1.2 Transformations 
 
KIX plasmid was transformed into BL21 (DE3) competent E. coli cells using the 
following protocol. BL21 (DE3) cells contain the gene for T7 RNA polymerase under 
the control of lacUV5 promoter. Therefore, T7 polymerase can be induced by lactose 
or Isopropyl β-D-1-thiogalactopyranoside (IPTG) allowing maximal expression of the 
genes cloned downstream of T7 promoter. 
1. Gently mix 10 μL of BL21(DE3) cells and 1uL of 1 ng/μL KIX plasmid in a 
centrifuge tube. 
2. Incubate on ice for 10 minutes. 
 
3. Heat shock at 42 ⁰C for 30 seconds. 
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4. Incubate on ice for 2 minutes. 
 
5. Add 100 μL of SOC and incubate in the shaker incubator at 37 ⁰C and 200 
RPM for 1 hour. 
6. Plate cells on a kanamycin resistant plate and incubate at 37 ⁰C overnight. 
 
7. For a negative control, take 10 μL of cells and repeat steps 2 through 6. 
 
8. Store the plates in the refrigerator the next morning until use. 
 
 
 
 
 
 
Figure 22: pET-28a Vector map. The gene was codon optimized for E. coli and inserted 
between Xho I and BamH I sites. Image is taken from Novagen. 
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5.1.3 Expression 
 
Transformed E. coli colonies containing KIX plasmid that are not more than 
seven days old were grown in minimal medium (M9 medium) for expression and 
subsequent lysis. Protein was usually expressed in 2 L of M9 medium using the 
following recipe. 
Recipe for making 2 L of M9 medium: To 1700 mL of water add 
 
1. 200 mL of 10X M9 salts 
 
To make 2 L of 10X M9 salts add: 
 
a. Na2HPO4 120g 
 
b. KH2PO4 60g 
 
c. NaCl 10g 
 
d. Do NOT pH 
 
2. 4 mL of 1 M MgSO4 
 
3. 4 mL of 50 mM CaCl2 
 
4. 2 mL of 0.01 M FeCl3 
 
5. 400 μL of 5 mg/mL vitamin B1 
 
6. 20 % D-Glucose 
 
7. pH the solution to 7.3 – 7.5. 
 
8. Bring it up to 2 L and filter sterilize into two 1 L bottles. Take 2 mL of this 
media in a 15-mL falcon tube and label it as – N – Kan + cells (Control 
1) 
9. Add 1 g of ammonium chloride to each 1 L media and shake. Take 2 mL 
of this media in a falcon tube and label it as + N – Kan + cells (Control 
2) 
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10. Add 500 μL of 60 mg/L of kanamycin to each 1 L media and shake. Take 
2 mL of this media in a falcon tube and label it as + N + Kan – cells 
(Control 3) 
A 50 mL of starter culture (along with controls) was inoculated with colonies 
from fresh transformations and allowed to grow at 37 ⁰C with constant aeration for 15 
– 17 hours and was then used to start the main culture at an O.D of 0.04 measured at 
a wavelength of 600 nm. Cells were allowed to grow at 37 ⁰C until they reached an 
O.D of 0.6 and induced with 1 mM IPTG at 15 ⁰C. Culture was incubated for protein 
expression at 15 ⁰C for 22 hours (induction time tested for maximum protein 
expression level; Figure 23). Cells were then harvested by centrifugation at 7168 RCF 
for five minutes and stored at -80 ⁰C until purification. Samples of cells were collected 
pre- and post-induction for SDS-PAGE analysis of protein expression. 
 
 
5.1.4 KIX Purification Scheme 
 
Pellets from 1 L culture were usually purified at once. Harvested cells were 
resuspended in 25 mL of nickel lysis/load buffer (recipe at the end of section 5.1.3.1) 
with one PierceTM Protease Inhibitor tablet dissolved. The resuspended cells were 
lysed using French pressure cell press and centrifuged at 38000 RCF for one hour. 
Cell lysate was then run through a nickel column containing 35 mL of Ni-NTA resin on 
a Fast Protein Liquid Chromatography (FPLC) system – either Biologic Duo flow or 
NGC systems, both purchased from BioRad. The six-histidine tag sticks to nickel 
column. Purification procedure of the protein through nickel column is described below 
in detail. 
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Figure 23: KIX expression gel. The above figure shows expression levels of KIX 16- 
24 hours post-induction. Culture was grown in 1 L M9 medium and induced at 15 ⁰C 
with 1 mM IPTG. Gel was run on a 6-16 % SDS gel at 195 V for 45 minutes. 
 
 
5.1.4.1 Purification through nickel column. Nickel column was initially 
equilibrated with one column volume of nickel lysis/load buffer and then the column 
was charged with cell lysate. Column was then washed with one column volume of 
nickel lysis buffer during which most of the E. coli proteins pass through the column 
while KIX protein that is attached to six histidine tag sticks to the nickel column. 
Column is then washed with two column volumes of nickel wash buffer (a mixture of 
85% of nickel lysis buffer and 15 % of nickel elution buffer mixed by the FPLC system 
during the purification run according to a protocol pre-defined by the user). During this 
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step, any proteins that are bound non-specifically to the column are washed off. 
Column is then washed with two column volumes of nickel elution buffer. In this step, 
the high concentration of imidazole in the elution buffer elutes the protein (Figure 24 
and Figure 25). Buffers were run through the column at a flow rate of 3 mL/min 
throughout the purification procedure while lysate was loaded onto the column at a 
flow rate of 2 mL/min. Fractions from the flow through, wash and elute steps were 
always analysed by SDS-PAGE and the clean elute fractions were collected for 
subsequent purification. Eluted KIX protein along with the six-histidine tag and the 
thrombin cleavage site results in a 12 kDa peptide. Protein was concentrated and 
dialysed in gel filtration buffer for cleaving. KIX was found to precipitate at a 
concentration of 220 μM in elution buffer. It was therefore ensured that the protein was 
never concentrated above 200 μM in this step. Protein concentrations are determined 
as described in section 5.8. Nickel buffers and gel filtration buffer recipes are detailed 
below. 
a. Ni lysis/load buffer 
 
i. 50 mM sodium phosphate monobasic monohydrate (NaH2PO4) 
 
ii. 300 mM sodium chloride (NaCl) 
 
iii. 10 mM imidazole 
 
iv. 0.02 % sodium azide (NaN3) 
 
v. pH 8 
  
 
 
 
 
Figure 24: Pre-cleaved KIX purification by nickel column. Above figure shows the chromatogram of 1L KIX purified on a nickel 
column by BioRad NGC FPLC system. Solid blue line shows U.V absorbance throughout the run. Solid black line represents the 
percentage of buffer B running at every phase in the run. Fractions 1-9 represent the flow through peak, fractions 13-15 represent 
the wash peak and fractions 21-27 represent the elution peak. 
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b. Ni Elution buffer 
 
i. 50 mM sodium phosphate monobasic monohydrate (NaH2PO4) 
 
ii. 300 mM sodium chloride (NaCl) 
 
iii. 250 mM imidazole 
 
iv. 0.02 % sodium azide (NaN3) 
 
v. pH 8 
 
c. Gel Filtration Buffer (GFB) 
 
i. 50 mM sodium phosphate monobasic monohydrate (NaH2PO4) 
 
ii. 300 mM sodium Chloride (NaCl) 
 
iii. 1 mM EDTA 
 
iv. 0.02 % sodium azide (NaN3) 
 
v. pH 7 
 
5.1.4.2 Thrombin cleavage. Six histidine tag was cleaved from the protein 
using thrombin cleave kit purchased from Sigma Aldrich. Removal of tag was achieved 
by incubating the protein, having been dialysed in GFB, with thrombin beads for two 
hours. A cleave test was performed initially to determine the minimum time required 
for complete cleaving. Protein samples were collected before incubating with thrombin 
beads and periodically during incubation of protein with the beads. Samples were 
analysed on a SDS gel (Figure 26) and it was seen that two hours of incubation is 
sufficient for complete cleaving. Two hours of cleaving was used for subsequent 
protein preparations. Upon cleaving, two residues are left over from the thrombin 
cleave site namely Glycine and Serine. Thrombin cleavage results in a 10 kDa protein 
which was always analysed on a SDS gel to ensure complete cleaving. Cleaved 
protein was concentrated to 4-6 mL to run on size exclusion column to remove any 
impurities left over from nickel column purification. 
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Figure 25: SDS-PAGE gel of KIX purification through nickel column. Above gel 
shows the samples taken from cell lysate after lysis and centrifugation (Supernatant 
and pellet). It also shows samples taken from the flow through, wash and elute peak 
fractions obtained after purification through nickel column. 
 
5.1.4.3 Protein purification through size exclusion column. Size exclusion 
column separates proteins based on the size of the protein. Multiple injections with 
small volumes are usually run to ensure good resolution. 2 mL injections at 1 mL/min 
flow rate was shown to work best with our proteins. All size exclusion columns were 
run on a GE HiLoad XK 16/60 Superdex 75 pg column with a resin volume of 120 mL. 
Size exclusion purification scheme is described below (Figure 26 and Figure 27). 
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Figure 26: SDS-PAGE gel of KIX cleavage and purification through SEC. Above 
figure shows the pre-cleaved and concentrated post-cleaved samples of KIX. It also 
shows the fractions from the impurity peak and KIX peak obtained after purification of 
KIX through size exclusion chromatography. 
 
 
Column is initially equilibrated with 1.25 column volumes of GFB and 2 mL of 
protein is loaded onto the column. Protein was then eluted with 1.5 column volumes 
of GFB separating the impurities from our protein of interest. Column is re-equilibrated 
with 0.25 column volumes of GFB before loading the next 2 mL of the protein onto the 
column. Fractions from the protein and impurity peak were always analysed by SDS 
gel (Figure 26) and clean fractions are pooled, concentrated and stored at 4 ⁰C until 
further use. Cleaned protein is generally immediately dialysed with NMR, CD or ITC 
buffers for subsequent analysis. 
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Figure 27: Chromatogram of KIX purified through size exclusion column. Above 
figure shows a single run KIX purified through size exclusion column on BioRad NGC 
system. Peak under fractions 1-3 represents the impurity and peak under fractions 10- 
16 represent the pure KIX protein. Image has been cropped to show just the peak 
portion. Equilibration of the column with GFB before the run and in between multiple 
runs are not shown in the above figure. 
 
 
5.2 c-Myb Sample Preparation and Purification 
 
 
5.2.1 Cloning 
 
The human c-Myb gene (residues 275-327) sub-cloned into a modified pRSET- 
A vector was a kind gift from Dr. Jane Clarke (University of Cambridge). Details of 
modifications in the vector are described below. The vector is selected for ampicillin 
resistance and consists of a T7 promoter which is followed by a six-histidine tag 
(Figure 28). The Xpress Epitope EK region was removed. An insert consisting of GB1 
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tag, which helps to increase the solubility of the protein, followed by thrombin cleavage 
site and c-Myb gene was inserted between BamHI and EcoRI sites. 
 
 
 
 
 
Figure 28: Vector map of pRSET A, B and C vectors. pRSET A, B and C are similar 
to each other. They have different open reading frames in the gene coding the N- 
terminal peptide and their multiple cloning sites vary a bit. Image is taken from Thermo 
Fisher Scientific. 
 
 
5.2.2 Transformations 
 
c-Myb plasmid was transformed into C41 (DE3) competent E. coli cells using 
the following protocol. C41 (DE3) cells contain the gene for T7 RNA polymerase under 
the control of lacUV5 promoter just like the BL21 (DE3) cells. Therefore, T7 
polymerase can be induced by lactose or isopropyl β-D-1-thiogalactopyranoside 
(IPTG) allowing maximal expression of the genes cloned downstream of the T7 
promoter. 
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1. Gently mix 10 μL of C41(DE3) cells and 1uL of 1 ng/μL c-Myb WT/mutant 
plasmid in a centrifuge tube. 
2. Incubate on ice for thirty minutes. 
 
3. Heat shock at 42 ⁰C for 30 seconds. 
 
4. Incubate on ice for 2 minutes. 
 
5. Add 100 μL of SOC and incubate in the shaker incubator at 37 ⁰C and 200 
RPM for 1 hour. 
6. Plate cells on an ampicillin resistant plate and incubate at 37 ⁰C overnight. 
 
7. For a negative control, take 10 μL of cells and repeat steps 2 through 6. 
 
8. Store the plates in the refrigerator the next morning until use. 
 
 
5.2.3 Expression 
 
Transformed E. coli colonies, containing c-Myb WT or mutant plasmid, that 
were not more than seven days old were grown in M9 medium for expression and 
subsequent lysis. Protein was usually expressed in 2 L of M9 medium using the same 
recipe that’s described for the expression of KIX protein with slight variations. M9 
medium and controls were made up of antibiotic ampicillin instead of kanamycin. 
Starter cultures along with controls were inoculated with colonies from fresh 
transformations, and allowed to grow at 37 ⁰C with constant aeration for 15 – 17 hours 
and then used to start the main culture at an O.D of 0.04 measured at a wavelength 
of 600 nm. Cells were allowed to grow at 37 ⁰C until they reached an O.D of 0.6 and 
were then induced with 1 mM IPTG at 37 ⁰C. Induction times for WT and mutants 
varied between 3-6 hrs. Expression tests were conducted and induction times required 
for maximum protein expression levels were selected for the WT and each mutant 
(Table 10). Following protein expression, cells were harvested by centrifugation at 
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7168 RCF for five minutes and stored at -80 ⁰C until later purification. Samples of cells 
were collected pre-and post-induction for SDS-PAGE analysis of protein expression. 
 
 
 
c-Myb peptide 
Duration of induction representing 
maximum protein expression levels 
(in hrs) 
WT 3 
P289A 3 
P289A P316A 3 
G311A 5 
E292D 4 
K293H 5 
K296H 6 
L300V 6 
L300P 4 
L300G 4 
 
 
 
Table 10: Protein induction times for c-Myb WT and its mutants. Table showing 
maximum protein expression levels for c-Myb WT and each mutant. c-Myb WT and all 
the mutants were induced at 37 ⁰C and an O.D of 0.6. Expression tests were 
conducted to determine the times to maximum protein expression levels after induction 
with IPTG. 
 
 
5.2.4 c-Myb Purification Scheme 
 
Pellets from 2L culture were usually purified at once. Harvested cells were 
resuspended in 25 mL of nickel lysis/load buffer, lysed and centrifuged as described 
in section 5.1.4. Purification procedure of the protein through nickel column is 
described below in detail. 
5.2.4.1 Purification through nickel column. Purification of cell lysate through 
nickel column was done as described in section 5.1.4.1 (Figure 29). Fractions from 
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the flow through, wash and elute steps were always analysed by SDS-PAGE (Figure 
 
30) and the clean eluate fractions were collected for subsequent purification. Eluted c- 
Myb protein along with the six-histidine tag and the GB1 tag that includes thrombin 
cleavage site results in a 15 kDa residue. Protein was concentrated and dialysed in 
nickel load buffer for cleaving. 
 
 
 
 
Figure 29: Nickel column chromatogram of c-Myb. Above figure shows the 
chromatogram of 2L c-Myb culture run on BioRad Biologic DuoFlow system. Green 
solid line indicates U.V absorbance and the black solid line indicates the percentage 
of buffer B running through the column at different stages of chromatography. Peak 
under fractions 1-8 represents the flow through peak, peak under fractions 10-16 
represents the wash peak and the peak under fractions 22-28 represents elution peak. 
 
 
5.2.4.2 Thrombin cleavage. Six histidine tag along with GB1 tag was cleaved 
from the protein using thrombin cleave kit purchased from Sigma Aldrich. Removal of 
tag was achieved by incubating the protein, that is dialysed in nickel load buffer, with 
thrombin beads from the kit. A cleave test was performed on WT and all mutant c-Myb 
proteins and it was seen that 3 hours of incubation with thrombin beads is sufficient 
for complete cleaving. Protein samples were collected before incubating with thrombin 
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beads and periodically during incubation of protein with the beads. Upon cleaving, two 
residues are left over from the thrombin cleave site namely glycine and serine. 
Thrombin cleavage results in a 6 kDa protein and 9 kDa tag (histidine tag and GB1 tag 
together) which were always analysed on a SDS gel (Figure 31) to ensure complete 
cleaving. Cleaved protein was run on a Nickel column again to separate the 9 kDa tag 
from the 6 kDa protein. 
 
 
 
Figure 30: SDS-PAGE gel of pre-cleaved c-Myb. Above figure shows a 2L culture 
purification of c-Myb mutant L300P. It shows c-Myb at various steps from pre-induction 
to purification after nickel column. Pre- and post-inductions samples are also shown 
on the same gel. Flow through, wash and elute peak fractions represent fractions 
obtained through nickel column purification. 
 
 
5.2.4.3 Protein purification through post-cleave nickel column. Nickel 
column was run with the same parameters described in section 5.1.4.1. In this 
purification step, cleaved c-Myb protein that is not attached to the six-histidine tag is 
collected in the flow through (F.T) fractions while the GB1 tag that is attached to the 
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six-histidine tag is collected in the elution fractions (Figure 32). Fractions from the F.T, 
wash and elute were run on a SDS gel for analysis (Figure 31). Clean flow through 
fractions were collected, concentrated to 4-6 mL and run on size exclusion column. 
 
 
 
 
Figure 31: SDS-PAGE gel of pre- and post-cleaved c-Myb and post-cleaved 
purification fractions. Concentrated pre- and post-cleaved samples of c-Myb are 
shown in the above picture. Above figure also shows F.T and elute peak fractions 
obtained from purification through nickel column after cleaving using thrombin beads. 
 
 
5.2.4.4 Protein purification through size exclusion column. Size exclusion 
column purification (Figure 33) was done as described in section 5.1.4.3. Fractions 
from the protein and impurity peaks were analysed by SDS gel electrophoresis (Figure 
34) and clean fractions were pooled, concentrated and stored in the fridge until further 
use. Cleaned protein is generally immediately dialysed with NMR, CD or ITC buffers 
for subsequent analysis. 
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Figure 32: Chromatogram of c-Myb purified through post-cleave nickel column. 
Above picture shows the chromatogram of a 2L culture of c-Myb P289A P316A purified 
through nickel column after cleaving with thrombin beads. Peak under fractions 1-12 
represent the flow through peak that contains cleaved protein and peak under fractions 
15-17 represent the tag peak that contains GB1 tag attached to six-histidine tag. 
 
 
5.3 Circular Dichroism 
 
Circular Dichroism (CD) can be used to study the secondary structure of 
proteins and their folding properties [175]. CD is defined as the difference in the 
absorption of left handed and right handed circularly polarized light by an asymmetric 
molecule, in this case our protein of interest. CD spectra were measured on a JASCO 
J-815 spectropolarimeter at 25 ⁰C and 10 ⁰C. Proteins were dialysed by million-fold 
with CD buffer (refer to the end of the section) prior to measurement. CD spectra for 
all the proteins were measured in the far-UV range (190 – 260 nm). Protein solution 
of 1 mg/mL was placed in a 0.1 mm path length cell and the spectra were acquired 
under constant purging with nitrogen at a bandwidth of 1 nm and a scanning speed of 
10 nm/min. Two spectra were collected for sample and averaged. 
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CD buffer 
 
i. 50 mM sodium phosphate monobasic monohydrate (NaH2PO4) 
 
ii. 50 mM sodium chloride (NaCl) 
 
iii. pH 6.8 
 
 
 
 
Figure 33: Chromatogram of c-Myb purified through size exclusion column. 
Above figure shows a single run of c-Myb L300P purified through size exclusion 
column on BioRad NGC system. Peaks under fractions 6-10 represent impurity peaks 
and peak under fractions 12-16 represent the pure c-Myb protein. Image has been 
cropped to show just the peak portion. Equilibration of the column with GFB before the 
run and in between multiple runs are not shown in the above figure. 
 
 
 
5.4 Nuclear Magnetic Resonance (NMR) Spectroscopy 
 
All NMR experiments were performed using 800 MHz Varian spectrometer. 
Uniformly labelled 15N and 13C proteins were made as described in the above sections. 
HSQC and HNCACB experiments were performed at 25 ⁰C or 10 ⁰C at a concentration 
range of 0.2-0.5 mM in 50 mM sodium phosphate, 50 mM sodium chloride, 1mM EDTA 
and 0.02% sodium azide with 10% D2O at pH 6.8. All NMR spectra were processed 
using NMRFx processor  [176]  and analysed  using NMRViewJ  [177].  Random coil 
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chemical shift data was collected from the ncIDP database to calculate the secondary 
chemical shift deviations. Residual helicity of each peptide is calculated from the 
obtained secondary chemical shift deviation data by using the δ2D program developed 
by Vendruscolo [173]. Proteins were dialysed by million-fold in the following buffer 
before analysis. 
NMR buffer 
 
i. 50 mM sodium phosphate monobasic monohydrate (NaH2PO4) 
 
ii. 50 mM sodium chloride (NaCl) 
 
iii. 0.02 % sodium azide 
 
iv. pH 6.8 
 
 
 
 
 
 
 
 
Figure 34: SDS-PAGE gel of c-Myb purified through size exclusion. Above figure 
shows samples taken from the fractions of impurity peak and the pure protein peak 
obtained after size exclusion column. 
75 
 
5.5 Isothermal Titration Calorimetry (ITC) 
 
All ITC experiments were conducted at 25 ⁰C using MicroCal VP-ITC isothermal 
titration calorimeter in 50 mM sodium phosphate, 150 mM sodium chloride, 1 mM 
EDTA and 0.02 % sodium azide at pH 6.8. KIX was loaded into the cell at a 
concentration of 15 μM and the injection syringe was loaded with either mutant or WT 
c-Myb at a concentration of 150 μM. A single ITC run is performed with 29 injections 
each with a volume of 10 μL injected at a flow rate of 0.5 μL/sec. Three such runs were 
performed with every protein and the average binding affinity values with standard 
deviations were reported. Experimental data obtained from ITC was analysed using 
the Origin70 ITC software. Data from 29 injections in each run was integrated and was 
fit using a single site binding model. Proteins were dialysed by million-fold in the 
following buffer before analysis. 
ITC buffer 
 
i. 50 mM sodium phosphate monobasic monohydrate (NaH2PO4) 
 
ii. 150 mM sodium chloride (NaCl) 
 
iii. 0.02 % sodium azide 
 
iv. pH 6.8 
 
 
5.6 Site Directed Mutagenesis 
 
Site directed mutagenesis was performed using the Stratagene QuickChange 
kit. QuickChange kit can be used to make single amino acid substitutions and 
insertions and deletions. Mutagenesis is performed using a supercoiled dsDNA 
(plasmid DNA) and oligonucleotide forward and reverse primers containing the desired 
mutation. Primers that are complimentary to the opposite strands of the plasmid DNA 
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are extended by PCR. Primers for the desired mutation were designed using PrimerX 
software and purchased from Operon. The following protocol was used. 
 
 
5.6.1 Setting up the Polymerase Chain Reaction 
 
1. Prepare a control reaction of 25 μL by adding: 
 
i. 2.5 μL of 10 X reaction buffer 
 
ii. 2 μL of pWhitescript 4.5 kb control plasmid (5 ng/μL) 
 
iii. 0.625 μL of oligonucleotide control primer 1 (100 ng/μL)] 
 
iv. 0.625 μL of oligonucleotide control primer 2 (100 ng/μL)] 
 
v. 0.500 μL of dNTP mix 
 
vi. Bring it up to a final volume of 25 μL with double distilled water. 
 
2. Prepare sample reactions with a range of template plasmid concentrations 
such as 2.5, 5, 10 and 25 ng. To each tube of sample reactions, add 
i. 2.5 μL of 10 X reaction buffer 
 
ii. Template plasmid at the above-mentioned concentrations (X μL of 
2.5 / 5 / 10 / 25 ng/μL) 
iii. 0.500 μL (125 ng/μL) of forward primer 
 
iv. 0.500 μL (125 ng/μL) of reverse primer 
 
v. 0.500 μL of dNTP mix 
 
vi. Bring it up to 25 μL with ddH2O 
 
3. Add 0.5 μL of PfuTurbo DNA polymerase to the control and sample 
reactions 
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5.6.2 Polymerase Chain Reaction 
 
In this step, plasmid with the target site for mutation is denatured and annealed 
with the oligonucleotides containing the desired mutation. Thermocycler was set up as 
shown in table 11. Tubes are stored in the refrigerator until the next step. 
 
 
Step Temperature Time No. of Cycles 
Initial denaturation 95 ⁰C 30 seconds 1 
Denaturation, 
Annealing and 
Extension 
95 ⁰C 30 seconds  
18 55 ⁰C 1 minute 
68 ⁰C 1 min/kb of plasmid 
Final extension 68 ⁰C 5 minutes 1 
Hold 4 ⁰C - - 
 
 
 
Table 11: Steps of polymerase chain reaction. Table showing the steps of 
polymerase chain reaction with temperatures, duration of each cycle and the no of 
cycles used for each step. 
 
 
5.6.3 Dpn I Digestion 
 
PCR results in nicked circular strands of both parental DNA and DNA with 
desired mutation. Parental DNA from the mixture is digested using Dpn I which is 
specific to methylated DNA. DNA from E. coli is dam methylated and is therefore 
susceptible to Dpn I digestion. Dpn I digestion is done as follows. 
i. Add 0.5 μL of Dpn I enzyme (10 U/μL). 
 
ii. Blip spin microfuge tubes. 
 
iii. Incubate at 37 ⁰C for 2 hours with agitation. 
 
iv. Store the tubes in refrigerator until next step. 
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5.6.4 Transformations 
 
Circular, nicked double-stranded mutated DNA is transformed using 
supercompetent XL1-Blue E. coli cells. After transformation, nicks in the mutated 
plasmid are repaired by XL1-Blue cells. Transformations were done using the following 
protocol. 
1. Add 25 μL of XL1-Blue cells to a sterile labelled micro centrifuge tube. 
 
2. Add 0.5 μL of Dpn I digested sample to respective tubes and mix gently. 
 
3. Set up a positive control reaction with XL1-Blue cells and pUC plasmid. 
 
4. Set up a mutagenesis control reaction with XL1-Blue cells and pWhitescript 
mutagenesis control plasmid. 
5. Incubate on ice for 30 minutes. 
 
6. Heat shock at 42 ⁰C for 30 seconds. 
 
7. Incubate on ice for 2 minutes. 
 
8. Add 125 μL of NZY+ broth to each tube and incubate for 1 hour 37 ⁰C in a 
shaker incubator at 200 RPM. 
9. Plate 250 μL of pWhitescript mutagenesis control on LB gar plates with 
appropriate antibiotic containing 80 μg/mL X-gal and 20 mM IPTG. 
10. Plate 5 μL of transformed pUC plasmid cells. 200 μL of NZY+ broth can be 
added to the plates for spreading. 
11. Plate entire transformation reaction of Dpn I digested plasmid. 
 
12. Incubate the plates at 37 ⁰C for more than 16 hours. 
 
There should be 50-800 mutant control colonies with 80% being blue. 
 
There should be >250 colonies of the transformation control with >98% being blue. 
There should be 10-1000 sample colonies. 
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5.6.5 Minipreps 
 
Minipreparation of plasmid DNA obtained from the above step was made from 
three to four isolated colonies and sent for sequencing to ensure that the right amino 
acid substitution was made. 
5.6.5.1 Overnight cultures. Four to five single colonies were picked from a 
freshly streaked plate to inoculate 5 mL of LB medium supplemented with appropriate 
antibiotic. Tubes with the cultures were incubated for 14-16 hours at 37 ⁰C on a shaker 
incubator with aeration. 15 mL falcon tubes were used for overnight cultures to attain 
proper aeration. Minipreps were done the following morning using GeneJET Plasmid 
Miniprep kit from Thermo Scientific according to the protocol described below. 
5.6.5.2 Purification of plasmid DNA. 
 
1. Harvest the cultures by centrifugation at 6800 x g for five minutes. 
 
2. Discard the supernatant and resuspend the pellet in 250 μL of the 
resuspension solution pre-mixed with RNAse A. Resuspend the pellet by 
pipetting up and down until no clumps are seen. 
3. Transfer the cell lysate to a microcentrifuge tube and add 250 μL of the 
lysis solution. Mix thoroughly by inverting the tube up and down until the 
solution becomes viscous and slightly clear. This step shouldn’t exceed more 
than five minutes. 
4. Add 250 μL of neutralisation buffer and mix thoroughly by inverting the 
tube up and down 4-6 times. The solution becomes cloudy. 
5. Centrifuge for 5 minutes at 12000 x g to pellet the cell debris. 
 
6. Transfer the supernatant to the GeneJET spin column provided by the 
kit. 
7. Centrifuge for 1 minute at 12000 x g and discard the flow through. 
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8. Add 500 μL of wash buffer and centrifuge for 1 minute at 12000 x g. 
 
Discard the flow through. 
 
9. Repeat the above step and centrifuge for an additional one minute to 
remove any remaining wash solution. 
10. Transfer the spin column to a sterilized 1.5 mL centrifuge tube. Add 20- 
50 μL of elution buffer to the center of the spin column and incubate for two 
minutes at room temperature. 
11. Centrifuge for two minutes at 12000 x g to elute the plasmid DNA. 
 
12. Store plasmids in the refrigerator. 
 
 
5.6.6 Determination of Plasmid DNA Purity and Sequencing 
 
Purity of the plasmid DNA was checked by U.V absorbance using ND-1000 
Nanodrop. Plasmid DNA purity can be estimated by measuring the ratios of 
absorbances at various wavelengths i.e., 260 nm / 280 nm and 260 nm / 230 nm. The 
260 nm / 280 nm ratio estimates the ratio of the amounts of nucleic acids and protein 
present in the sample. Ratio greater than 1.8 indicates low protein contamination. 260 
nm / 280 nm ratio estimates the contamination of organic solvents and chaotropic 
salts. A ratio of greater than 2.0 indicates a pure sample. Samples with desirable purity 
were sent to Eurofins MWG Operon for sequencing to ensure that the plasmid DNA 
has the right sequence. 
 
 
5.7 Sodium Dodecyl Sulphate – Polyacrylamide Gel Electrophoresis (SDS- 
PAGE) 
The separation of macromolecules under the influence of an electric field is 
called electrophoresis. SDS-PAGE is the most common type of electrophoresis used 
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to separate proteins. SDS is an anionic detergent that denatures proteins i.e., breaks 
down the complex tertiary structure of proteins making the polypeptide linear. SDS 
has a net negative charge and binds to linear polypeptide chains uniformly i.e., the 
charge of the polypeptide is proportional to its molecular weight thus allowing 
polypeptides to be separated solely by differences in molecular weight. Masking of 
polypeptides with SDS results in an overall negative charge on polypeptides attracting 
them towards anode in an electric field. 
Samples were generally run on a 6 % to 16 % gradient SDS gel at 195 V for 45 
minutes. Samples with complexes of KIX bound to mutant and WT were run on a 10 
% to 20 % gradient SDS gel at 195 V for 45 minutes. Molecular weights of cleaved 
KIX and cleaved c-Myb are 9 kDa and 6 kDa respectively and thus a 10 % to 20 % 
gradient gel allows a better resolution in the separation of both the molecules. 40 % 
acrylamide solution with 29:1 acrylamide/bisacrylamide composition was used to 
make all gels. 
 
 
5.8 Determination of Protein Concentration 
 
Concentration of proteins is determined by measuring the U.V absorbance of 
sample at 280 nm using NanoDrop ND-1000 Spectrophotometer. Concentration of the 
sample is calculated from the absorbance value at 280 nm using the Beer’s Law 
Equation i.e., Absorbance = e*L*c where ‘e’ is the molar extinction coefficient, ‘L’ is 
the path length of the cell holder and ‘c’ is the concentration of the solution. Molar 
extinction coefficients were calculated using the ProtParam tool provided by ExPAsy: 
SIB Bioinformatics Resource Portal. 
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APPENDICES 
 
 
Appendix A: Chemical Shifts Tables of Mutant and WT c-Myb 
Table A1. c-Myb WT Chemical Shifts 
 
 
Residue CO CB CA N HN 
P 176.251648 31.9837093 63.395771   
A 177.64209 19.1026306 52.5764198 124.217903 8.31011009 
A 177.64209 19.1777191 52.5184784 122.844193 8.10978031 
A 177.74147 19.1612301 52.5113792 122.844193 8.10978031 
A 177.805115 19.1250191 52.5675011 123.112343 8.15645981 
I 176.801651 38.706871 61.1877708 119.833977 7.94857979 
Q 175.567673 29.4332008 55.702919 124.410347 8.31521034 
R 175.62117 30.9693203 55.8497391 122.57386 8.25009251 
H 174.663742 30.5723801 55.7702293 120.528023 8.36273956 
Y 175.344482 39.0033913 57.9470406 121.819237 8.18362999 
N 174.801315 39.0571404 53.1883507 120.481697 8.51933956 
D 176.118149 41.1490517 54.7804184 120.7649 8.25166988 
E 175.969894 30.3205891 56.4079094 120.092346 8.23711014 
D  41.5247612 52.1508217 122.293633 8.33296585 
P 178.363571 32.2467117 64.2790527   
E 177.673996 29.4087296 57.4385681 118.486214 8.37530994 
K 177.834854 32.5905991 58.7876511 120.894569 7.70233011 
E 177.952209 29.5658493 58.4550095 118.676239 8.13712025 
K 178.074249 32.6411285 58.4596901 120.362953 7.86625004 
R 178.074249 30.3211994 57.8246994   
I 177.802597 38.0331001 63.6509285 120.535843 7.98291016 
K 178.444061 32.227169 58.2094116 121.750847 7.99701977 
E 178.49115 29.7106991 58.6601295 119.747589 8.1718502 
L 178.672684 41.9338112 57.1037292 120.840157 7.97055006 
E 178.379105 29.8735104 58.6294098 119.796982 8.13099957 
L 178.87825 41.967659 56.8112984 119.997749 7.84325981 
L 178.659241 42.0739403 56.6159401 121.14859 7.85596991 
L 178.146713 41.97369 56.2192993 120.654701 8.00646973 
101 
 
Residue CO CB CA N HN 
M 176.803207 32.8791695 56.2530594 118.894569 7.95686007 
S 175.288483 63.7126007 58.9786491 115.932518 8.11594963 
T 175.126801 69.59095 62.6361504 115.724358 8.15273952 
E 176.834793 29.9831009 57.4510384 122.273293 8.33024025 
N 175.752365 38.9301987 53.9741096 118.611122 8.29827023 
E 176.902603 30.1086502 57.3457603 121.053787 8.26537991 
L 177.734085 41.9289589 55.524559 122.033363 8.14163017 
K 177.36174 32.8578796 56.7266006 121.216743 8.10945034 
G 174.247452  44.7326813 109.141586 8.29001999 
Q 175.903793 29.5503597 55.7700005 119.459084 8.12030029 
Q 175.646729 29.5394001 55.8062096 121.496887 8.36600018 
V 175.813919 32.7392807 62.1061516 121.976791 8.1723299 
L  41.8241615 52.8375282 127.59005 8.33372974 
P 177.071472 32.0555611 63.1059494   
T 174.625351 69.59095 61.85 113.777023 8.07275963 
Q  29.9831009 55.7450104 122.25383 8.32050991 
N      
H 175.275528 30.30937 56.2547493   
T 174.16095 69.7615509 61.9369698 115.542633 8.08308029 
A 177.365311 19.3240604 52.5523987 126.207626 8.26251984 
S 173.492157 63.7662392 58.0805702 114.608559 8.05494976 
Y  38.4071312 55.4808807 123.029411 7.98932981 
P 176.993896 31.7978401 63.4661713   
G 172.969543  45.2038498 108.569702 7.71261978 
W  29.9346294 58.4260292 125.815163 7.44950008 
 
 
 
Table A2. c-Myb P289A Chemical Shifts 
 
 
 
 
Residue CO CB CA N HN 
P 176.6 31.94 63.15 138.91  
A 177.56 18.97 52.43 124.47 8.39 
A 177.67 18.98 52.57 123.26 8.19 
A 177.67 18.98 52.57 123.26 8.19 
A 177.93 19.06 52.63 123.1 8.17 
I 176.41 38.43 61.31 119.79 8.04 
Q 175.84 29.44 55.49 124.36 8.47 
R 175.99 30.67 55.97 122.76 8.32 
102 
 
Residue CO CB CA N HN 
H 174.25 29.7 55.84 120.45 8.47 
Y 175.19 38.64 57.76 121.77 8.14 
N 174.34 38.89 52.89 121.02 8.31 
D 176.43 40.95 54.55 120.81 8.33 
E 176.33 30.12 56.84 121.08 8.38 
D 176.14 40.99 54.32 121.43 8.34 
A 177.97 18.99 52.82 124.49 8.22 
E 176.56 30.1 56.53 121.41 8.54 
K 176.34 32.88 56.49 122.21 8.39 
E 176.49 30.15 56.7 122.15 8.42 
K 176.66 32.78 56.44 121.97 8.26 
R 176.15 30.68 56.15 122.43 8.33 
I 176.13 38.55 61.13 122.49 8.16 
K 176.68 32.88 56.25 125.46 8.46 
E 176.4 30.07 56.66 121.68 8.39 
L 177.5 42.16 55.36 123 8.25 
E 176.4 30.03 56.55 121.21 8.32 
L 177.39 42.04 55.25 122.71 8.18 
L 177.31 42.02 55.16 122.31 8.11 
L 177.65 41.86 55.28 122.57 8.13 
M 176.35 32.63 55.52 120.78 8.31 
S 174.79 63.71 58.26 117.42 8.46 
T 174.49 69.71 62.01 116.22 8.26 
E 176.15 30.14 56.73 123.23 8.49 
N 175.29 38.74 53.33 119.79 8.53 
E 176.46 29.97 56.76 121.07 8.35 
L 177.49 42.12 55.29 123.17 8.21 
K 177.11 32.78 56.49 122.19 8.33 
G 173.96 9999 45.33 110.01 8.46 
Q 175.96 29.51 55.74 120.14 8.24 
Q 175.69 29.49 55.75 121.88 8.43 
V 176.01 32.56 62.29 121.71 8.18 
L 174.97 41.64 52.91 127.46 8.32 
P 177.1 32.02 63.14 137.52 9999 
T 174.53 69.65 61.85 114.51 8.32 
Q 175.53 29.42 55.92 122.69 8.45 
N 175 38.77 53.11 120.14 8.46 
H 174.97 29.6 56.13 119.7 8.48 
T 174.06 69.72 61.81 115.78 8.13 
A 177.81 19.12 52.59 126.53 8.37 
103 
 
Residue CO CB CA N HN 
S 174.46 63.65 58.36 114.91 8.21 
Y 173.28 38.17 55.49 123.6 8.23 
P 176.91 32.09 62.94 139.34 9999 
G 173.9 9999 45.06 109.08 8.63 
W      
 
 
 
Table A3. c-Myb P289A P316A Chemical Shifts 
 
 
 
 
Residue CO CB CA N HN 
P 176.6 31.94 63.15 138.91  
A 177.56 18.97 52.43 124.47 8.39 
A 177.67 18.98 52.57 123.26 8.19 
A 177.67 18.98 52.57 123.26 8.19 
A 177.93 19.06 52.63 123.1 8.17 
I 176.41 38.43 61.31 119.79 8.04 
Q 175.84 29.44 55.49 124.36 8.47 
R 175.99 30.67 55.97 122.76 8.32 
H 174.25 29.7 55.84 120.45 8.47 
Y 175.19 38.64 57.76 121.77 8.14 
N 174.34 38.89 52.89 121.02 8.31 
D 176.43 40.95 54.55 120.81 8.33 
E 176.33 30.12 56.84 121.08 8.38 
D 176.14 40.99 54.32 121.43 8.34 
A 177.97 18.99 52.82 124.49 8.22 
E 176.67 30.12 56.67 120.2 8.34 
K 176.69 32.87 56.51 122.48 8.38 
E 176.49 30.15 56.7 122.15 8.42 
K 176.57 32.85 56.32 122.51 8.36 
R 176.15 30.68 56.15 122.43 8.33 
I 176.13 38.55 61.13 122.49 8.16 
K 176.68 32.88 56.25 125.46 8.46 
E 176.4 30.07 56.66 121.68 8.39 
L 177.5 42.16 55.36 123 8.25 
E 176.4 30.03 56.55 121.21 8.32 
L 177.39 42.04 55.25 122.71 8.18 
L 177.31 42.02 55.16 122.31 8.11 
L 177.65 41.86 55.28 122.57 8.13 
104 
 
Residue CO CB CA N HN 
M 176.35 32.63 55.52 120.78 8.31 
S 174.79 63.71 58.26 117.42 8.46 
T 174.49 69.71 62.01 116.22 8.26 
E 176.15 30.14 56.73 123.23 8.49 
N 175.29 38.74 53.33 119.79 8.53 
E 176.46 29.97 56.76 121.07 8.35 
L 177.49 42.12 55.29 123.17 8.21 
K 177.11 32.78 56.49 122.19 8.33 
G 173.96 9999 45.33 110.01 8.46 
Q 175.96 29.51 55.74 120.14 8.24 
Q 175.69 29.49 55.75 121.88 8.43 
V 176.01 32.56 62.29 121.71 8.18 
L 177.02 42.08 55.15 126.38 8.29 
A 177.98 19.04 52.56 124.82 8.3 
T 174.64 69.66 61.99 113.3 8.12 
Q 175.53 29.42 55.92 122.69 8.45 
N 175 38.77 53.11 120.14 8.46 
H 174.97 29.6 56.13 119.7 8.48 
T 174.06 69.72 61.81 115.78 8.13 
A 177.81 19.12 52.59 126.53 8.37 
S 174.46 63.65 58.36 114.91 8.21 
Y 173.28 38.17 55.49 123.6 8.23 
P 176.91 32.09 62.94 139.34 9999 
G 173.9  45.06 109.08 8.63 
 
 
 
Table A4. c-Myb E292D Chemical Shifts 
 
 
 
 
Residue CO CB CA N HN 
P 176.6 31.94 63.15 138.91  
A 177.56 18.97 52.43 124.47 8.39 
A 177.67 18.98 52.57 123.26 8.19 
A 177.67 18.98 52.57 123.26 8.19 
A 177.93 19.06 52.63 123.1 8.17 
I 176.41 38.43 61.31 119.79 8.04 
Q 175.84 29.44 55.49 124.36 8.47 
R 175.99 30.67 55.97 122.76 8.32 
H 174.25 29.7 55.84 120.45 8.47 
105 
 
Residue CO CB CA N HN 
Y 175.19 38.64 57.76 121.77 8.14 
N 174.34 38.89 52.89 121.02 8.31 
D 176.43 40.95 54.55 120.81 8.33 
E 176.33 30.12 56.84 121.08 8.38 
D 174.08 40.54 52.08 122.5 8.36 
P 177.1 31.96 63.4 137.19 9999 
E 176.56 30.1 56.53 121.41 8.54 
K 176.34 32.88 56.49 122.21 8.39 
D 176.35 41.02 54.38 121.59 8.34 
K 176.66 32.78 56.44 121.97 8.26 
R 176.15 30.68 56.15 122.43 8.33 
I 176.13 38.55 61.13 122.49 8.16 
K 176.68 32.88 56.25 125.46 8.46 
E 176.4 30.07 56.66 121.68 8.39 
L 177.5 42.16 55.36 123 8.25 
E 176.4 30.03 56.55 121.21 8.32 
L 177.39 42.04 55.25 122.71 8.18 
L 177.31 42.02 55.16 122.31 8.11 
L 177.65 41.86 55.28 122.57 8.13 
M 176.35 32.63 55.52 120.78 8.31 
S 174.79 63.71 58.26 117.42 8.46 
T 174.49 69.71 62.01 116.22 8.26 
E 176.15 30.14 56.73 123.23 8.49 
N 175.29 38.74 53.33 119.79 8.53 
E 176.46 29.97 56.76 121.07 8.35 
L 177.49 42.12 55.29 123.17 8.21 
K 177.11 32.78 56.49 122.19 8.33 
G 173.96 9999 45.33 110.01 8.46 
Q 175.96 29.51 55.74 120.14 8.24 
Q 175.69 29.49 55.75 121.88 8.43 
V 176.01 32.56 62.29 121.71 8.18 
L 174.97 41.64 52.91 127.46 8.32 
P 177.1 32.02 63.14 137.52 9999 
T 174.53 69.65 61.85 114.51 8.32 
Q 175.53 29.42 55.92 122.69 8.45 
N 175 38.77 53.11 120.14 8.46 
H 174.97 29.6 56.13 119.7 8.48 
T 174.06 69.72 61.81 115.78 8.13 
A 177.81 19.12 52.59 126.53 8.37 
106 
 
Residue CO CB CA N HN 
S 174.46 63.65 58.36 114.91 8.21 
Y 173.28 38.17 55.49 123.6 8.23 
P 176.91 32.09 62.94 139.34 9999 
G 173.9  45.06 109.08 8.63 
 
 
 
Table A5. c-Myb L300G Chemical Shifts 
 
 
 
 
Residue CO CB CA N HN 
P 176.6 31.94 63.15 138.91  
A 177.56 18.97 52.43 124.47 8.39 
A 177.67 18.98 52.57 123.26 8.19 
A 177.67 18.98 52.57 123.26 8.19 
A 177.93 19.06 52.63 123.1 8.17 
I 176.41 38.43 61.31 119.79 8.04 
Q 175.84 29.44 55.49 124.36 8.47 
R 175.99 30.67 55.97 122.76 8.32 
H 174.25 29.7 55.84 120.45 8.47 
Y 175.19 38.64 57.76 121.77 8.14 
N 174.34 38.89 52.89 121.02 8.31 
D 176.43 40.95 54.55 120.81 8.33 
E 176.33 30.12 56.84 121.08 8.38 
D 174.08 40.54 52.08 122.5 8.36 
P 177.1 31.96 63.4 137.19 9999 
E 176.56 30.1 56.53 121.41 8.54 
K 176.69 32.87 56.51 122.48 8.38 
E 176.49 30.15 56.7 122.15 8.42 
K 176.57 32.85 56.32 122.51 8.36 
R 176.15 30.68 56.15 122.43 8.33 
I 176.13 38.55 61.13 122.49 8.16 
K 176.68 32.88 56.25 125.46 8.46 
E 176.4 30.07 56.66 121.68 8.39 
L 177.5 42.16 55.36 123 8.25 
E 177.01 30.08 56.73 121.6 8.41 
G 173.99 9999 45.22 109.61 8.39 
L 177.43 42.16 55.08 121.48 8 
L 177.65 41.86 55.28 122.57 8.13 
107 
 
Residue CO CB CA N HN 
M 176.35 32.63 55.52 120.78 8.31 
S 174.79 63.71 58.26 117.42 8.46 
T 174.49 69.71 62.01 116.22 8.26 
E 176.15 30.14 56.73 123.23 8.49 
N 175.29 38.74 53.33 119.79 8.53 
E 176.46 29.97 56.76 121.07 8.35 
L 177.49 42.12 55.29 123.17 8.21 
K 177.11 32.78 56.49 122.19 8.33 
G 173.96 9999 45.33 110.01 8.46 
Q 175.96 29.51 55.74 120.14 8.24 
Q 175.69 29.49 55.75 121.88 8.43 
V 176.01 32.56 62.29 121.71 8.18 
L 174.97 41.64 52.91 127.46 8.32 
P 177.1 32.02 63.14 137.52 9999 
T 174.53 69.65 61.85 114.51 8.32 
Q 175.53 29.42 55.92 122.69 8.45 
N 175 38.77 53.11 120.14 8.46 
H 174.97 29.6 56.13 119.7 8.48 
T 174.06 69.72 61.81 115.78 8.13 
A 177.81 19.12 52.59 126.53 8.37 
S 174.46 63.65 58.36 114.91 8.21 
Y 173.28 38.17 55.49 123.6 8.23 
P 176.91 32.09 62.94 139.34 9999 
G 173.9  45.06 109.08 8.63 
 
 
 
Table A6. c-Myb L300P Chemical Shifts 
 
 
 
 
Residue CO CB CA N HN 
P 176.6 31.94 63.15 138.91  
A 177.56 18.97 52.43 124.47 8.39 
A 177.67 18.98 52.57 123.26 8.19 
A 177.67 18.98 52.57 123.26 8.19 
A 177.93 19.06 52.63 123.1 8.17 
I 176.41 38.43 61.31 119.79 8.04 
Q 175.84 29.44 55.49 124.36 8.47 
R 175.99 30.67 55.97 122.76 8.32 
108 
 
Residue CO CB CA N HN 
H 174.25 29.7 55.84 120.45 8.47 
Y 175.19 38.64 57.76 121.77 8.14 
N 174.34 38.89 52.89 121.02 8.31 
D 176.43 40.95 54.55 120.81 8.33 
E 176.33 30.12 56.84 121.08 8.38 
D 174.08 40.54 52.08 122.5 8.36 
P 177.1 31.96 63.4 137.19 9999 
E 176.56 30.1 56.53 121.41 8.54 
K 176.69 32.87 56.51 122.48 8.38 
E 176.49 30.15 56.7 122.15 8.42 
K 176.57 32.85 56.32 122.51 8.36 
R 176.15 30.68 56.15 122.43 8.33 
I 176.13 38.55 61.13 122.49 8.16 
K 176.68 32.88 56.25 125.46 8.46 
E 176.4 30.07 56.66 121.68 8.39 
L 177.5 42.16 55.36 123 8.25 
E 174.14 29.66 54.31 122.68 8.38 
P 177.1 32.02 63.14 137.52 9999 
L 177.39 42.01 55.1 122.05 8.29 
L 177.65 41.86 55.28 122.57 8.13 
M 176.35 32.63 55.52 120.78 8.31 
S 174.79 63.71 58.26 117.42 8.46 
T 174.49 69.71 62.01 116.22 8.26 
E 176.15 30.14 56.73 123.23 8.49 
N 175.29 38.74 53.33 119.79 8.53 
E 176.46 29.97 56.76 121.07 8.35 
L 177.49 42.12 55.29 123.17 8.21 
K 177.11 32.78 56.49 122.19 8.33 
G 173.96 9999 45.33 110.01 8.46 
Q 175.96 29.51 55.74 120.14 8.24 
Q 175.69 29.49 55.75 121.88 8.43 
V 176.01 32.56 62.29 121.71 8.18 
L 174.97 41.64 52.91 127.46 8.32 
P 177.1 32.02 63.14 137.52 9999 
T 174.53 69.65 61.85 114.51 8.32 
Q 175.53 29.42 55.92 122.69 8.45 
N 175 38.77 53.11 120.14 8.46 
H 174.97 29.6 56.13 119.7 8.48 
T 174.06 69.72 61.81 115.78 8.13 
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Residue CO CB CA N HN 
A 177.81 19.12 52.59 126.53 8.37 
S 174.46 63.65 58.36 114.91 8.21 
Y 173.28 38.17 55.49 123.6 8.23 
P 176.91 32.09 62.94 139.34 9999 
G 173.9  45.06 109.08 8.63 
 
 
 
Appendix B: Agadir Prediction Plots 
 
Agadir predictions in the segment of c-Myb TAD that forms an alpha helix was 
plotted for WT and mutants 
 
 
Figure B1. c-Myb WT Agadir Plot 
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Figure B2. c-Myb E292D Agadir Plot 
 
 
 
 
 
 
 
Figure B3. c-Myb K293H Agadir Plot 
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Figure B4. c-Myb K296H Agadir Plot 
 
 
 
 
 
 
 
Figure B5. c-Myb L300V Agadir Plot 
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Figure B6. c-Myb L300G Agadir Plot 
 
 
 
 
 
 
 
Figure B7. c-Myb L300P Agadir Plot 
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Figure C1: License for use of published material 
 
 
 
